{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:24:31Z","timestamp":1794464671153,"version":"4.9.1"},"reference-count":498,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) remains the most aggressive and lethal brain tumor in adults and poses significant challenges to patient survival. This review provides a comprehensive exploration of the molecular and genetic landscape of GBM, focusing on key oncogenic drivers, such as epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and the PI3K\/AKT\/mTOR pathway, which are critical for tumorigenesis and progression. We delve into the role of epigenetic alterations, including DNA methylation and histone modifications, in driving therapy resistance and tumor evolution. The tumor microenvironment is known for its pivotal role in immune evasion, with tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells creating an immunosuppressive niche that sustains GBM growth. Emerging therapies, such as immunotherapies, oncolytic viral therapies, extracellular vesicle-based approaches, and non-coding RNA interventions, are highlighted as promising avenues to disrupt GBM pathogenesis. Advances in precision medicine and innovative technologies, including electric field therapy and locoregional treatments, are discussed for their potential to overcome the blood\u2012brain barrier and treatment resistance. Additionally, this review underscores the importance of metabolic reprogramming, particularly hypoxia-driven adaptations and altered lipid metabolism, in fueling GBM progression and influencing the therapeutic response. The role of glioma stem cells in tumor recurrence and resistance is also emphasized, highlighting the need for targeted therapeutic approaches. By integrating molecular targeting, immune energetics, and technological advancements, this review outlines a multidisciplinary framework for improving GBM treatment outcomes. Ultimately, the convergence of genetic, metabolic, and immune-based strategies offers transformative potential in GBM management, paving the way for increased patient survival and quality of life.<\/jats:p>","DOI":"10.1038\/s41392-025-02299-4","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:42:10Z","timestamp":1752136930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":346,"title":["Glioblastoma at the crossroads: current understanding and future therapeutic horizons"],"prefix":"10.1038","volume":"10","author":[{"given":"Shilpi","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanjan","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashis","family":"Barik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iteeshree","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peize","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4721-1513","authenticated-orcid":false,"given":"Amar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gatikrushna","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2299_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 22, iv1\u2013iv96 (2020).","journal-title":"Neuro Oncol."},{"key":"2299_CR2","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","volume":"164","author":"SH Torp","year":"2022","unstructured":"Torp, S. H., Solheim, O. & Skjulsvik, A. J. The WHO 2021 classification of central nervous system tumours: a practical update on what neurosurgeons need to know-a minireview. Acta Neurochir. 164, 2453\u20132464 (2022).","journal-title":"Acta Neurochir."},{"key":"2299_CR3","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3390\/genes14091693","volume":"14","author":"JP Br\u00e1s","year":"2023","unstructured":"Br\u00e1s, J. P. et al. TERTmonitor-qPCR detection of TERTp mutations in glioma. Genes 14, 1693 (2023).","journal-title":"Genes"},{"key":"2299_CR4","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s13311-022-01238-3","volume":"19","author":"JJ Miller","year":"2022","unstructured":"Miller, J. J. Targeting IDH-mutant glioma. Neurotherapeutics 19, 1724\u20131732 (2022).","journal-title":"Neurotherapeutics"},{"key":"2299_CR5","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","volume":"122","author":"S Han","year":"2020","unstructured":"Han, S. et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br. J. Cancer 122, 1580\u20131589 (2020).","journal-title":"Br. J. Cancer"},{"key":"2299_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163450","volume":"133","author":"BL McClellan","year":"2023","unstructured":"McClellan, B. L. et al. Impact of epigenetic reprogramming on antitumor immune responses in glioma. J. Clin. Investig. 133, e163450 (2023).","journal-title":"J. Clin. Investig."},{"key":"2299_CR7","doi-asserted-by":"publisher","first-page":"8324","DOI":"10.3390\/ijms22158324","volume":"22","author":"Q Wu","year":"2021","unstructured":"Wu, Q., Berglund, A. E. & Etame, A. B. The impact of epigenetic modifications on adaptive resistance evolution in glioblastoma. Int. J. Mol. Sci. 22, 8324 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/stmcls\/sxac088","volume":"41","author":"H Yan","year":"2023","unstructured":"Yan, H. et al. The heterogeneous cellular states of glioblastoma stem cells revealed by single cell analysis. Stem Cells 41, 111\u2013125 (2023).","journal-title":"Stem Cells"},{"key":"2299_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/0008-5472.CAN-23-0609","volume":"84","author":"X Guo","year":"2024","unstructured":"Guo, X. et al. Neuronal activity promotes glioma progression by inducing proneural-to-mesenchymal transition in glioma stem cells. Cancer Res 84, 372\u2013387 (2024).","journal-title":"Cancer Res"},{"key":"2299_CR10","doi-asserted-by":"publisher","first-page":"14960","DOI":"10.3390\/ijms241914960","volume":"24","author":"S Singh","year":"2023","unstructured":"Singh, S. et al. Unveiling novel avenues in mTOR-targeted therapeutics: advancements in glioblastoma treatment. Int. J. Mol. Sci. 24, 14960 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR11","first-page":"vdad009","volume":"5","author":"P Sharma","year":"2023","unstructured":"Sharma, P., Aaroe, A., Liang, J. & Puduvalli, V. K. Tumor microenvironment in glioblastoma: current and emerging concepts. Neurooncol. Adv. 5, vdad009 (2023).","journal-title":"Neurooncol. Adv."},{"key":"2299_CR12","doi-asserted-by":"publisher","first-page":"1238233","DOI":"10.3389\/fimmu.2023.1238233","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang, L., Jiang, Y., Zhang, G. & Wei, S. The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma. Front. Immunol. 14, 1238233 (2023).","journal-title":"Front. Immunol."},{"key":"2299_CR13","doi-asserted-by":"publisher","first-page":"100049","DOI":"10.1016\/j.vesic.2024.100049","volume":"4","author":"S Singh","year":"2024","unstructured":"Singh, S., Chen, C. C., Kim, S., Singh, A. & Singh, G. Role of Extracellular vesicle microRNAs and RNA binding proteins on glioblastoma dynamics and therapeutics development. Extracell. Vesicle 4, 100049 (2024).","journal-title":"Extracell. Vesicle"},{"key":"2299_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11523-020-00717-x","volume":"15","author":"M Ratti","year":"2020","unstructured":"Ratti, M. et al. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target. Oncol. 15, 261\u2013278 (2020).","journal-title":"Target. Oncol."},{"key":"2299_CR15","doi-asserted-by":"publisher","first-page":"101730","DOI":"10.1016\/j.tranon.2023.101730","volume":"35","author":"KR Uppaluri","year":"2023","unstructured":"Uppaluri, K. R. et al. Unlocking the potential of non-coding RNAs in cancer research and therapy. Transl. Oncol. 35, 101730 (2023).","journal-title":"Transl. Oncol."},{"key":"2299_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/bpa.12572","volume":"28","author":"N Nakajima","year":"2017","unstructured":"Nakajima, N. et al. BRAF V600E, TERT promoter mutations and CDKN2A\/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. Brain Pathol. 28, 663\u2013673 (2017).","journal-title":"Brain Pathol."},{"key":"2299_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803\u2013820 (2016).","journal-title":"Acta Neuropathol."},{"key":"2299_CR18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"2299_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","volume":"9","author":"HS Phillips","year":"2006","unstructured":"Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157\u2013173 (2006).","journal-title":"Cancer Cell"},{"key":"2299_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RGW Verhaak","year":"2010","unstructured":"Verhaak, R. G. W. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98\u2013110 (2010).","journal-title":"Cancer Cell"},{"key":"2299_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fonc.2017.00146","volume":"7","author":"A Sharma","year":"2017","unstructured":"Sharma, A. et al. Angiogenic gene signature derived from subtype specific cell models segregate proneural and mesenchymal glioblastoma. Front. Oncol. 7, 146 (2017).","journal-title":"Front. Oncol."},{"key":"2299_CR22","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"2299_CR23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41417-019-0142-6","volume":"27","author":"H Ma","year":"2020","unstructured":"Ma, H. et al. Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns. Cancer Gene Ther. 27, 702\u2013714 (2020).","journal-title":"Cancer Gene Ther."},{"key":"2299_CR24","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41388-017-0077-z","volume":"37","author":"RJ Molenaar","year":"2018","unstructured":"Molenaar, R. J., Maciejewski, J. P., Wilmink, J. W. & van Noorden, C. J. F. Wild-type and mutated IDH1\/2 enzymes and therapy responses. Oncogene 37, 1949\u20131960 (2018).","journal-title":"Oncogene"},{"key":"2299_CR25","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-12-1773","volume":"18","author":"H Yang","year":"2012","unstructured":"Yang, H., Ye, D., Guan, K.-L. & Xiong, Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin. Cancer Res. 18, 5562\u20135571 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-013-0345-4","volume":"13","author":"AL Cohen","year":"2013","unstructured":"Cohen, A. L., Holmen, S. L. & Colman, H. IDH1 and IDH2 mutations in gliomas. Curr. Neurol. Neurosci. Rep. 13, 345 (2013).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"2299_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1349-7006.2011.02175.x","volume":"103","author":"A Mukasa","year":"2012","unstructured":"Mukasa, A. et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 103, 587\u2013592 (2012).","journal-title":"Cancer Sci."},{"key":"2299_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11060-012-0977-2","volume":"110","author":"TA Juratli","year":"2012","unstructured":"Juratli, T. A. et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J. Neurooncol. 110, 325\u2013333 (2012).","journal-title":"J. Neurooncol."},{"key":"2299_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-022-03960-6","volume":"157","author":"A Ramos-Fresnedo","year":"2022","unstructured":"Ramos-Fresnedo, A. et al. The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J. Neurooncol. 157, 177\u2013185 (2022).","journal-title":"J. Neurooncol."},{"key":"2299_CR30","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1101\/gr.132738.111","volume":"22","author":"CG Duncan","year":"2012","unstructured":"Duncan, C. G. et al. A heterozygous IDH1R132H\/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 22, 2339\u20132355 (2012).","journal-title":"Genome Res"},{"key":"2299_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/neuonc\/not159","volume":"16","author":"J Beiko","year":"2014","unstructured":"Beiko, J. et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 16, 81\u201391 (2014).","journal-title":"Neuro Oncol."},{"key":"2299_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1215\/15228517-2009-025","volume":"11","author":"K Ichimura","year":"2009","unstructured":"Ichimura, K. et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 11, 341\u2013347 (2009).","journal-title":"Neuro Oncol."},{"key":"2299_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765\u2013773 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2299_CR34","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S1470-2045(13)70168-2","volume":"14","author":"M Weller","year":"2013","unstructured":"Weller, M. et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol. 14, e370\u2013e379 (2013).","journal-title":"Lancet Oncol."},{"key":"2299_CR35","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."},{"key":"2299_CR36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","volume":"13","author":"W Wick","year":"2012","unstructured":"Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomized, phase 3 trial. Lancet Oncol. 13, 707\u2013715 (2012).","journal-title":"Lancet Oncol."},{"key":"2299_CR37","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m, A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized, phase 3 trial. Lancet Oncol. 13, 916\u2013926 (2012).","journal-title":"Lancet Oncol."},{"key":"2299_CR38","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1200\/JCO.2013.49.6067","volume":"31","author":"TS Armstrong","year":"2013","unstructured":"Armstrong, T. S. et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 31, 4076\u20134084 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2299_CR39","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-23-1295","volume":"29","author":"CJ Kinslow","year":"2023","unstructured":"Kinslow, C. J. et al. MGMT promoter methylation predicts overall survival after chemotherapy for 1p\/19q-codeleted gliomas. Clin. Cancer Res. 29, 4399\u20134407 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/cancers16020331","volume":"16","author":"Q Fang","year":"2024","unstructured":"Fang, Q. The versatile attributes of MGMT: its repair mechanism, crosstalk with other DNA repair pathways, and itS ROLE IN CANCer. Cancers 16, 331 (2024).","journal-title":"Cancers"},{"key":"2299_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1148\/radiol.2532090007","volume":"253","author":"RF Barajas","year":"2009","unstructured":"Barajas, R. F. et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 253, 486\u2013496 (2009).","journal-title":"Radiology"},{"key":"2299_CR42","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nm.2682","volume":"18","author":"C Choi","year":"2012","unstructured":"Choi, C. et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 18, 624\u2013629 (2012).","journal-title":"Nat. Med."},{"key":"2299_CR43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00234-012-1127-4","volume":"55","author":"VA Larsen","year":"2013","unstructured":"Larsen, V. A., Simonsen, H. J., Law, I., Larsson, H. B. W. & Hansen, A. E. Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology 55, 361\u2013369 (2013).","journal-title":"Neuroradiology"},{"key":"2299_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.14791\/btrt.2015.3.1.8","volume":"3","author":"MC Mabray","year":"2015","unstructured":"Mabray, M. C., Barajas, R. F. & Cha, S. Modern brain tumor imaging. Brain Tumor Res. Treat. 3, 8\u201323 (2015).","journal-title":"Brain Tumor Res. Treat."},{"key":"2299_CR45","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1118\/1.4948668","volume":"43","author":"P Korfiatis","year":"2016","unstructured":"Korfiatis, P. et al. MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Med. Phys. 43, 2835\u20132844 (2016).","journal-title":"Med. Phys."},{"key":"2299_CR46","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2967\/jnumed.111.102533","volume":"53","author":"T Singhal","year":"2012","unstructured":"Singhal, T., Narayanan, T. K., Jacobs, M. P., Bal, C. & Mantil, J. C. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J. Nucl. Med. 53, 1709\u20131715 (2012).","journal-title":"J. Nucl. Med."},{"key":"2299_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00259-004-1598-6","volume":"32","author":"S Kim","year":"2005","unstructured":"Kim, S. et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur. J. Nucl. Med. Mol. Imaging 32, 52\u201359 (2005).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2299_CR48","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.110.078592","volume":"51","author":"BJ Fueger","year":"2010","unstructured":"Fueger, B. J. et al. Correlation of 6-18F-fluoro-L-DOPA PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J. Nucl. Med. 51, 1532\u20131538 (2010).","journal-title":"J. Nucl. Med."},{"key":"2299_CR49","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00401-015-1399-y","volume":"129","author":"MG Best","year":"2015","unstructured":"Best, M. G. et al. Liquid biopsies in patients with diffuse glioma. Acta Neuropathol. 129, 849\u2013865 (2015).","journal-title":"Acta Neuropathol."},{"key":"2299_CR50","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41416-019-0603-6","volume":"122","author":"J M\u00fcller Bark","year":"2020","unstructured":"M\u00fcller Bark, J., Kulasinghe, A., Chua, B., Day, B. W. & Punyadeera, C. Circulating biomarkers in patients with glioblastoma. Br. J. Cancer 122, 295\u2013305 (2020).","journal-title":"Br. J. Cancer"},{"key":"2299_CR51","doi-asserted-by":"publisher","first-page":"19545","DOI":"10.1021\/acsami.8b06072","volume":"10","author":"H Cui","year":"2018","unstructured":"Cui, H. et al. Frosted slides decorated with silica nanowires for detecting circulating tumor cells from prostate cancer patients. ACS Appl. Mater. Interfaces 10, 19545\u201319553 (2018).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2299_CR52","doi-asserted-by":"publisher","first-page":"607150","DOI":"10.3389\/fonc.2021.607150","volume":"11","author":"H Zhang","year":"2021","unstructured":"Zhang, H., Yuan, F., Qi, Y., Liu, B. & Chen, Q. Circulating tumor cells for glioma. Front. Oncol. 11, 607150 (2021).","journal-title":"Front. Oncol."},{"key":"2299_CR53","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/onc.2015.192","volume":"35","author":"K Pantel","year":"2016","unstructured":"Pantel, K. & Speicher, M. R. The biology of circulating tumor cells. Oncogene 35, 1216\u20131224 (2016).","journal-title":"Oncogene"},{"key":"2299_CR54","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41556-021-00639-4","volume":"23","author":"X Gao","year":"2021","unstructured":"Gao, X. et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR\u2013STAT3 signaling. Nat. Cell Biol. 23, 278\u2013291 (2021).","journal-title":"Nat. Cell Biol."},{"key":"2299_CR55","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41388-017-0019-9","volume":"37","author":"M Zhang","year":"2018","unstructured":"Zhang, M. et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene 37, 1805\u20131814 (2018).","journal-title":"Oncogene"},{"key":"2299_CR56","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/cells11142130","volume":"11","author":"SP Ahmed","year":"2022","unstructured":"Ahmed, S. P., Castresana, J. S. & Shahi, M. H. Role of circular RNA in brain tumor development. Cells 11, 2130 (2022).","journal-title":"Cells"},{"key":"2299_CR57","doi-asserted-by":"publisher","first-page":"117363","DOI":"10.1016\/j.lfs.2020.117363","volume":"245","author":"J Qiao","year":"2020","unstructured":"Qiao, J., Liu, M., Tian, Q. & Liu, X. Microarray analysis of circRNAs expression profile in gliomas reveals that circ_0037655 could promote glioma progression by regulating miR-214\/PI3K signaling. Life Sci. 245, 117363 (2020).","journal-title":"Life Sci."},{"key":"2299_CR58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuroscience.2021.12.037","volume":"494","author":"P Chen","year":"2022","unstructured":"Chen, P. et al. CircXRCC5, as a potential novel biomarker, promotes glioma progression via the miR-490-3p\/XRCC5\/CLC3 competing endogenous RNA network. Neuroscience 494, 104\u2013118 (2022).","journal-title":"Neuroscience"},{"key":"2299_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-022-00979-6","volume":"8","author":"Q Wu","year":"2022","unstructured":"Wu, Q., Yin, X., Zhao, W., Xu, W. & Chen, L. Molecular mechanism of m6A methylation of circDLC1 mediated by RNA methyltransferase METTL3 in the malignant proliferation of glioma cells. Cell Death Discov. 8, 1\u201311 (2022).","journal-title":"Cell Death Discov."},{"key":"2299_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01485-6","volume":"21","author":"Z Pan","year":"2022","unstructured":"Pan, Z. et al. EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. Mol. Cancer 21, 16 (2022).","journal-title":"Mol. Cancer"},{"key":"2299_CR61","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.canlet.2021.09.030","volume":"522","author":"B Chen","year":"2021","unstructured":"Chen, B. et al. Circular RNA circLGMN facilitates glioblastoma progression by targeting miR-127-3p\/LGMN axis. Cancer Lett. 522, 225\u2013237 (2021).","journal-title":"Cancer Lett."},{"key":"2299_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2023.110599","volume":"115","author":"G Yang","year":"2023","unstructured":"Yang, G. et al. lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p\/RAB31 axis. Genomics 115, 110599 (2023).","journal-title":"Genomics"},{"key":"2299_CR63","doi-asserted-by":"publisher","first-page":"8871746","DOI":"10.1155\/2020\/8871746","volume":"2020","author":"J-C Mei","year":"2020","unstructured":"Mei, J.-C., Yan, G. & Mei, S.-Q. Diagnostic and prognostic potentials of long noncoding RNA ELF3-AS1 in glioma patients. Dis. Markers 2020, 8871746 (2020).","journal-title":"Dis. Markers"},{"key":"2299_CR64","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1111\/jcmm.15189","volume":"24","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. SOX9-activated PXN-AS1 promotes the tumorigenesis of glioblastoma by EZH2-mediated methylation of DKK1. J. Cell. Mol. Med. 24, 6070\u20136082 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"2299_CR65","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fcell.2020.00642","volume":"8","author":"Z Tu","year":"2020","unstructured":"Tu, Z. et al. N6-Methylandenosine-related lncRNAs are potential biomarkers for predicting the overall survival of lower-grade glioma patients. Front. Cell Dev. Biol. 8, 642 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"2299_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0822-0","volume":"17","author":"SK Tan","year":"2018","unstructured":"Tan, S. K. et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. Mol. Cancer 17, 74 (2018).","journal-title":"Mol. Cancer"},{"key":"2299_CR67","doi-asserted-by":"publisher","first-page":"144518","DOI":"10.1016\/j.gene.2020.144518","volume":"739","author":"Y Baspinar","year":"2020","unstructured":"Baspinar, Y., Elmaci, I., Ozpinar, A. & Altinoz, M. A. Long non-coding RNA MALAT1 as a key target in pathogenesis of glioblastoma. Janus faces or Achilles\u2019 heal?. Gene 739, 144518 (2020).","journal-title":"Gene"},{"key":"2299_CR68","first-page":"1","volume":"11","author":"C Xue","year":"2021","unstructured":"Xue, C., Chen, C., Gu, X. & Li, L. Progress and assessment of lncRNA DGCR5 in malignant phenotype and immune infiltration of human cancers. Am. J. Cancer Res. 11, 1\u201313 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"2299_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02153-x","volume":"21","author":"Z Zhao","year":"2021","unstructured":"Zhao, Z. et al. Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma. Cancer Cell Int. 21, 456 (2021).","journal-title":"Cancer Cell Int."},{"key":"2299_CR70","doi-asserted-by":"publisher","first-page":"803652","DOI":"10.3389\/fonc.2022.803652","volume":"12","author":"S Wu","year":"2022","unstructured":"Wu, S. et al. LncRNA GAS5 represses stemness and malignancy of gliomas via elevating the SPACA6-miR-125a\/let-7e axis. Front. Oncol. 12, 803652 (2022).","journal-title":"Front. Oncol."},{"key":"2299_CR71","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/ijms17091431","volume":"17","author":"Q-L Lv","year":"2016","unstructured":"Lv, Q.-L. et al. A long noncoding RNA ZEB1-AS1 promotes tumorigenesis and predicts poor prognosis in glioma. Int. J. Mol. Sci. 17, 1431 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR72","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1746-1596-8-200","volume":"8","author":"L Wu","year":"2013","unstructured":"Wu, L. et al. MicroRNA-21 expression is associated with overall survival in patients with glioma. Diagn. Pathol. 8, 200 (2013).","journal-title":"Diagn. Pathol."},{"key":"2299_CR73","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.toxrep.2020.11.001","volume":"7","author":"A-M Aloizou","year":"2020","unstructured":"Aloizou, A.-M. et al. The role of MiRNA-21 in gliomas: hope for a novel therapeutic intervention? Toxicol. Rep. 7, 1514\u20131530 (2020).","journal-title":"Toxicol. Rep."},{"key":"2299_CR74","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11060-017-2639-x","volume":"136","author":"A Santangelo","year":"2018","unstructured":"Santangelo, A. et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J. Neurooncol. 136, 51\u201362 (2018).","journal-title":"J. Neurooncol."},{"key":"2299_CR75","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/neuonc\/nou169","volume":"17","author":"F Zhi","year":"2015","unstructured":"Zhi, F. et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol. 17, 383\u2013391 (2015).","journal-title":"Neuro Oncol."},{"key":"2299_CR76","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ebiom.2019.03.016","volume":"42","author":"J Yin","year":"2019","unstructured":"Yin, J. et al. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. EBioMedicine 42, 238\u2013251 (2019).","journal-title":"EBioMedicine"},{"key":"2299_CR77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13402-017-0355-3","volume":"41","author":"F Lan","year":"2018","unstructured":"Lan, F. et al. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell. Oncol. 41, 25\u201333 (2018).","journal-title":"Cell. Oncol."},{"key":"2299_CR78","doi-asserted-by":"publisher","first-page":"105652","DOI":"10.1016\/j.clineuro.2019.105652","volume":"190","author":"A Tabibkhooei","year":"2020","unstructured":"Tabibkhooei, A. et al. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas. Clin. Neurol. Neurosurg. 190, 105652 (2020).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"2299_CR79","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2017.07.022","volume":"406","author":"K Zhao","year":"2017","unstructured":"Zhao, K. et al. EGFR\/c-myc axis regulates TGF\u03b2\/Hippo\/Notch pathway via epigenetic silencing miR-524 in gliomas. Cancer Lett. 406, 12\u201321 (2017).","journal-title":"Cancer Lett."},{"key":"2299_CR80","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.3390\/cancers14133217","volume":"14","author":"P Mahinfar","year":"2022","unstructured":"Mahinfar, P. et al. The role of microRNAs in multidrug resistance of glioblastoma. Cancers 14, 3217 (2022).","journal-title":"Cancers"},{"key":"2299_CR81","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1158\/0008-5472.CAN-13-1449","volume":"74","author":"J Kim","year":"2014","unstructured":"Kim, J. et al. microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. Cancer Res. 74, 1541\u20131553 (2014).","journal-title":"Cancer Res."},{"key":"2299_CR82","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/onc.2012.132","volume":"32","author":"D Yin","year":"2013","unstructured":"Yin, D. et al. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 32, 1155\u20131163 (2013).","journal-title":"Oncogene"},{"key":"2299_CR83","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.omtn.2019.05.022","volume":"17","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. miR-340-5p suppresses aggressiveness in glioblastoma multiforme by targeting Bcl-w and Sox2. Mol. Ther. Nucleic Acids 17, 245\u2013255 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2299_CR84","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.3390\/ijms25084221","volume":"25","author":"P Jarmuzek","year":"2024","unstructured":"Jarmuzek, P., Wawrzyniak-Gramacka, E., Morawin, B., Tylutka, A. & Zembron-Lacny, A. Diagnostic and prognostic value of circulating DNA fragments in glioblastoma multiforme patients. Int. J. Mol. Sci. 25, 4221 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR85","doi-asserted-by":"publisher","first-page":"7974","DOI":"10.3390\/ijms25147974","volume":"25","author":"AA Seyhan","year":"2024","unstructured":"Seyhan, A. A. CirculatinG Liquid Biopsy Biomarkers In Glioblastoma: Advances And Challenges. Int. J. Mol. Sci. 25, 7974 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR86","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","volume":"24","author":"OA Zill","year":"2018","unstructured":"Zill, O. A. et al. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin. Cancer Res. 24, 3528\u20133538 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR87","doi-asserted-by":"publisher","first-page":"CNS34","DOI":"10.2217\/cns-2018-0015","volume":"8","author":"DE Piccioni","year":"2019","unstructured":"Piccioni, D. E. et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 8, CNS34 (2019).","journal-title":"CNS Oncol."},{"key":"2299_CR88","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","volume":"565","author":"AM Miller","year":"2019","unstructured":"Miller, A. M. et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature 565, 654\u2013658 (2019).","journal-title":"Nature"},{"key":"2299_CR89","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/biomedicines10010125","volume":"10","author":"C Cilibrasi","year":"2022","unstructured":"Cilibrasi, C. et al. Definition of an inflammatory biomarker signature in plasma-derived extracellular vesicles of glioblastoma patients. Biomedicines 10, 125 (2022).","journal-title":"Biomedicines"},{"key":"2299_CR90","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/1078-0432.CCR-18-1941","volume":"25","author":"D Osti","year":"2019","unstructured":"Osti, D. et al. Clinical significance of extracellular vesicles in plasma from glioblastoma patients. Clin. Cancer Res. 25, 266\u2013276 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR91","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3389\/fonc.2019.00651","volume":"9","author":"LM Cumba Garcia","year":"2019","unstructured":"Cumba Garcia, L. M., Peterson, T. E., Cepeda, M. A., Johnson, A. J. & Parney, I. F. Isolation and analysis of plasma-derived exosomes in patients with glioma. Front. Oncol. 9, 651 (2019).","journal-title":"Front. Oncol."},{"key":"2299_CR92","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/nm.2994","volume":"18","author":"H Shao","year":"2012","unstructured":"Shao, H. et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat. Med. 18, 1835\u20131840 (2012).","journal-title":"Nat. Med."},{"key":"2299_CR93","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/neuonc\/noae068","volume":"26","author":"FL Ricklefs","year":"2024","unstructured":"Ricklefs, F. L. et al. Circulating extracellular vesicles as biomarker for diagnosis, prognosis, and monitoring in glioblastoma patients. Neuro Oncol. 26, 1280\u20131291 (2024).","journal-title":"Neuro Oncol."},{"key":"2299_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.28","volume":"2","author":"WW Chen","year":"2013","unstructured":"Chen, W. W. et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol. Ther. Nucleic Acids 2, e109 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2299_CR95","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/neuonc\/nox085","volume":"19","author":"JM Figueroa","year":"2017","unstructured":"Figueroa, J. M. et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 19, 1494\u20131502 (2017).","journal-title":"Neuro Oncol."},{"key":"2299_CR96","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3171\/2016.11.JNS161187","volume":"128","author":"SV Manda","year":"2018","unstructured":"Manda, S. V. et al. Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas. J. Neurosurg. 128, 1091\u20131101 (2018).","journal-title":"J. Neurosurg."},{"key":"2299_CR97","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/genes11111276","volume":"11","author":"M Vaidya","year":"2020","unstructured":"Vaidya, M. & Sugaya, K. DNA associated with circulating exosomes as a biomarker for glioma. Genes 11, 1276 (2020).","journal-title":"Genes"},{"key":"2299_CR98","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14791\/btrt.2014.2.1.7","volume":"2","author":"YZ Kim","year":"2014","unstructured":"Kim, Y. Z. Altered histone modifications in gliomas. Brain Tumor Res. Treat. 2, 7\u201321 (2014).","journal-title":"Brain Tumor Res. Treat."},{"key":"2299_CR99","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.canlet.2012.04.008","volume":"342","author":"S Kreth","year":"2014","unstructured":"Kreth, S., Thon, N. & Kreth, F. W. Epigenetics in human gliomas. Cancer Lett. 342, 185\u2013192 (2014).","journal-title":"Cancer Lett."},{"key":"2299_CR100","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/NEN.0b013e3182898113","volume":"72","author":"S Venneti","year":"2013","unstructured":"Venneti, S. et al. Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. J. Neuropathol. Exp. Neurol. 72, 298\u2013306 (2013).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2299_CR101","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226\u2013231 (2012).","journal-title":"Nature"},{"key":"2299_CR102","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1126\/science.1232245","volume":"340","author":"PW Lewis","year":"2013","unstructured":"Lewis, P. W. et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340, 857\u2013861 (2013).","journal-title":"Science"},{"key":"2299_CR103","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/cells10010124","volume":"10","author":"J-P Bryant","year":"2021","unstructured":"Bryant, J.-P., Heiss, J. & Banasavadi-Siddegowda, Y. K. Arginine methylation in brain tumors: tumor biology and therapeutic strategies. Cells 10, 124 (2021).","journal-title":"Cells"},{"key":"2299_CR104","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/cancers11060878","volume":"11","author":"M Romani","year":"2019","unstructured":"Romani, M., Daga, A., Forlani, A., Pistillo, M. P. & Banelli, B. Targeting of histone demethylases KDM5A and KDM6B inhibits the proliferation of temozolomide-resistant glioblastoma cells. Cancers 11, 878 (2019).","journal-title":"Cancers"},{"key":"2299_CR105","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","volume":"39","author":"R Chen","year":"2020","unstructured":"Chen, R. et al. The application of histone deacetylases inhibitors in glioblastoma. J. Exp. Clin. Cancer Res. 39, 138 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2299_CR106","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1750-3639.2011.00507.x","volume":"22","author":"N Schmidt","year":"2012","unstructured":"Schmidt, N., Windmann, S., Reifenberger, G. & Riemenschneider, M. J. DNA hypermethylation and histone modifications downregulate the candidate tumor suppressor gene RRP22 on 22q12 in human gliomas. Brain Pathol. 22, 17\u201325 (2012).","journal-title":"Brain Pathol."},{"key":"2299_CR107","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14728222.2018.1487953","volume":"22","author":"S Haase","year":"2018","unstructured":"Haase, S. et al. Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin. Ther. Targets 22, 599\u2013613 (2018).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2299_CR108","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fonc.2017.00236","volume":"7","author":"P Nandakumar","year":"2017","unstructured":"Nandakumar, P., Mansouri, A. & Das, S. The role of ATRX in glioma biology. Front. Oncol. 7, 236 (2017).","journal-title":"Front. Oncol."},{"key":"2299_CR109","doi-asserted-by":"publisher","first-page":"e1167158","DOI":"10.1080\/23723556.2016.1167158","volume":"3","author":"C Koschmann","year":"2016","unstructured":"Koschmann, C., Lowenstein, P. R. & Castro, M. G. ATRX mutations and glioblastoma: impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Mol. Cell. Oncol. 3, e1167158 (2016).","journal-title":"Mol. Cell. Oncol."},{"key":"2299_CR110","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrg3230","volume":"13","author":"PA Jones","year":"2012","unstructured":"Jones, P. A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 484\u2013492 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"2299_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01085-7","volume":"13","author":"VS Ferreyra","year":"2021","unstructured":"Ferreyra, V. S. et al. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clin. Epigenetics 13, 102 (2021).","journal-title":"Clin. Epigenetics"},{"key":"2299_CR112","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/neuonc\/noaa247","volume":"23","author":"J Dejaegher","year":"2021","unstructured":"Dejaegher, J. et al. DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro Oncol. 23, 240\u2013250 (2021).","journal-title":"Neuro Oncol."},{"key":"2299_CR113","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1038\/emm.2015.57","volume":"47","author":"D Zhou","year":"2015","unstructured":"Zhou, D. et al. DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells. Exp. Mol. Med. 47, e182\u2013e182 (2015).","journal-title":"Exp. Mol. Med."},{"key":"2299_CR114","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00401-018-1810-6","volume":"135","author":"P Bady","year":"2018","unstructured":"Bady, P. et al. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathol. 135, 601\u2013615 (2018).","journal-title":"Acta Neuropathol."},{"key":"2299_CR115","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","volume":"17","author":"BG Baumert","year":"2016","unstructured":"Baumert, B. G. et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomized, open-label, phase 3 intergroup study. Lancet Oncol. 17, 1521\u20131532 (2016).","journal-title":"Lancet Oncol."},{"key":"2299_CR116","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/1878-0261.12060","volume":"11","author":"Z Nawaz","year":"2017","unstructured":"Nawaz, Z. et al. Impact of somatic copy number alterations on the glioblastoma miRNome: miR-4484 is a genomically deleted tumour suppressor. Mol. Oncol. 11, 927\u2013944 (2017).","journal-title":"Mol. Oncol."},{"key":"2299_CR117","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/neuonc\/noy108","volume":"20","author":"PJ Cimino","year":"2018","unstructured":"Cimino, P. J. et al. Copy number profiling across glioblastoma populations has implications for clinical trial design. Neuro Oncol. 20, 1368\u20131373 (2018).","journal-title":"Neuro Oncol."},{"key":"2299_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1058-1","volume":"17","author":"M Seifert","year":"2016","unstructured":"Seifert, M., Friedrich, B. & Beyer, A. Importance of rare gene copy number alterations for personalized tumor characterization and survival analysis. Genome Biol. 17, 204 (2016).","journal-title":"Genome Biol."},{"key":"2299_CR119","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-017-0443-7","volume":"5","author":"PJ Cimino","year":"2017","unstructured":"Cimino, P. J. et al. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathol. Commun. 5, 39 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"2299_CR120","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/nov010","volume":"17","author":"S Spiegl-Kreinecker","year":"2015","unstructured":"Spiegl-Kreinecker, S. et al. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol. 17, 1231\u20131240 (2015).","journal-title":"Neuro Oncol."},{"key":"2299_CR121","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.prp.2018.04.002","volume":"214","author":"HS Kim","year":"2018","unstructured":"Kim, H. S. et al. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Pathol. Res. Pract. 214, 881\u2013888 (2018).","journal-title":"Pathol. Res. Pract."},{"key":"2299_CR122","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40478-017-0465-1","volume":"5","author":"Y Lee","year":"2017","unstructured":"Lee, Y. et al. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Acta Neuropathol. Commun. 5, 62 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"2299_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0123-z","volume":"8","author":"GL Ryland","year":"2015","unstructured":"Ryland, G. L. et al. Loss of heterozygosity: what is it good for?. BMC Med. Genom. 8, 45 (2015).","journal-title":"BMC Med. Genom."},{"key":"2299_CR124","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4103\/0028-3886.79139","volume":"59","author":"A Kakkar","year":"2011","unstructured":"Kakkar, A. et al. Loss of heterozygosity on chromosome 10q in glioblastomas, and its association with other genetic alterations and survival in Indian patients. Neurol. India 59, 254\u2013261 (2011).","journal-title":"Neurol. India"},{"key":"2299_CR125","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1373\/clinchem.2005.060954","volume":"52","author":"N Hata","year":"2006","unstructured":"Hata, N. et al. Allelic losses of chromosome 10 in glioma tissues detected by quantitative single-strand conformation polymorphism analysis. Clin. Chem. 52, 370\u2013378 (2006).","journal-title":"Clin. Chem."},{"key":"2299_CR126","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1111\/j.1349-7006.2009.01308.x","volume":"100","author":"H Ohgaki","year":"2009","unstructured":"Ohgaki, H. & Kleihues, P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 100, 2235\u20132241 (2009).","journal-title":"Cancer Sci."},{"key":"2299_CR127","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00401-014-1370-3","volume":"129","author":"DE Reuss","year":"2015","unstructured":"Reuss, D. E. et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an \u2018integrated\u2019 diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 129, 133\u2013146 (2015).","journal-title":"Acta Neuropathol."},{"key":"2299_CR128","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/neuonc\/nop075","volume":"12","author":"AP Vogazianou","year":"2010","unstructured":"Vogazianou, A. P. et al. Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol. 12, 664\u2013678 (2010).","journal-title":"Neuro Oncol."},{"key":"2299_CR129","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.2012.44.1444","volume":"31","author":"L Erdem-Eraslan","year":"2013","unstructured":"Erdem-Eraslan, L. et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J. Clin. Oncol. 31, 328\u2013336 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2299_CR130","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","volume":"21","author":"AL Di Stefano","year":"2015","unstructured":"Di Stefano, A. L. et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin. Cancer Res. 21, 3307\u20133317 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR131","doi-asserted-by":"publisher","first-page":"593578","DOI":"10.3389\/fonc.2020.593578","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Long, P., Wang, Y. & Ma, W. NTRK fusions and TRK inhibitors: potential targeted therapies for adult glioblastoma. Front. Oncol. 10, 593578 (2020).","journal-title":"Front. Oncol."},{"key":"2299_CR132","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1056\/NEJMc2101264","volume":"385","author":"A Bagchi","year":"2021","unstructured":"Bagchi, A. et al. Lorlatinib in a child with ALK-fusion-positive high-grade glioma. N. Engl. J. Med. 385, 761\u2013763 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2299_CR133","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","volume":"7","author":"A Drilon","year":"2017","unstructured":"Drilon, A. et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400\u2013409 (2017).","journal-title":"Cancer Discov."},{"key":"2299_CR134","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1101\/gr.165126.113","volume":"24","author":"Z-S Bao","year":"2014","unstructured":"Bao, Z.-S. et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 24, 1765\u20131773 (2014).","journal-title":"Genome Res."},{"key":"2299_CR135","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1158\/1078-0432.CCR-04-2115","volume":"11","author":"TW Vogel","year":"2005","unstructured":"Vogel, T. W. et al. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin. Cancer Res. 11, 3624\u20133632 (2005).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR136","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2015.09.002","volume":"60","author":"F Liu","year":"2015","unstructured":"Liu, F. et al. EGFR mutation promotes glioblastoma through epigenome and transcription factor network remodeling. Mol. Cell 60, 307\u2013318 (2015).","journal-title":"Mol. Cell"},{"key":"2299_CR137","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/156800912799277557","volume":"12","author":"TE Taylor","year":"2012","unstructured":"Taylor, T. E., Furnari, F. B. & Cavenee, W. K. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr. Cancer Drug Targets 12, 197\u2013209 (2012).","journal-title":"Curr. Cancer Drug Targets"},{"key":"2299_CR138","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fonc.2015.00005","volume":"5","author":"E Padfield","year":"2015","unstructured":"Padfield, E., Ellis, H. P. & Kurian, K. M. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front. Oncol. 5, 5 (2015).","journal-title":"Front. Oncol."},{"key":"2299_CR139","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1101\/gad.293027.116","volume":"31","author":"H Bulstrode","year":"2017","unstructured":"Bulstrode, H. et al. Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and epigenetic regulators. Genes Dev. 31, 757\u2013773 (2017).","journal-title":"Genes Dev."},{"key":"2299_CR140","doi-asserted-by":"publisher","first-page":"6781","DOI":"10.1523\/JNEUROSCI.0514-06.2006","volume":"26","author":"M Assanah","year":"2006","unstructured":"Assanah, M. et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J. Neurosci. 26, 6781\u20136790 (2006).","journal-title":"J. Neurosci."},{"key":"2299_CR141","first-page":"vdac097","volume":"4","author":"N Higa","year":"2022","unstructured":"Higa, N. et al. Prognostic impact of PDGFRA gain\/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma. Neurooncol. Adv. 4, vdac097 (2022).","journal-title":"Neurooncol. Adv."},{"key":"2299_CR142","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/bpa.12043","volume":"23","author":"JJ Phillips","year":"2013","unstructured":"Phillips, J. J. et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 23, 565\u2013573 (2013).","journal-title":"Brain Pathol."},{"key":"2299_CR143","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bpa.12768","volume":"30","author":"C Dufour","year":"2020","unstructured":"Dufour, C. et al. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant. Brain Pathol. 30, 179\u2013190 (2020).","journal-title":"Brain Pathol."},{"key":"2299_CR144","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ng.2682","volume":"45","author":"DTW Jones","year":"2013","unstructured":"Jones, D. T. W. et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 45, 927\u2013932 (2013).","journal-title":"Nat. Genet."},{"key":"2299_CR145","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ng.2611","volume":"45","author":"J Zhang","year":"2013","unstructured":"Zhang, J. et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 45, 602\u2013612 (2013).","journal-title":"Nat. Genet."},{"key":"2299_CR146","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1634\/theoncologist.2017-0242","volume":"22","author":"A Johnson","year":"2017","unstructured":"Johnson, A. et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist 22, 1478\u20131490 (2017).","journal-title":"Oncologist"},{"key":"2299_CR147","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a002378","volume":"4","author":"LY Ballester","year":"2018","unstructured":"Ballester, L. Y., Penas-Prado, M., Leeds, N. E., Huse, J. T. & Fuller, G. N. FGFR1 tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia. Cold Spring Harb. Mol. Case Stud. 4, a002378 (2018).","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"2299_CR148","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00401-019-01987-0","volume":"137","author":"DW Ellison","year":"2019","unstructured":"Ellison, D. W. et al. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathol. 137, 683\u2013687 (2019).","journal-title":"Acta Neuropathol."},{"key":"2299_CR149","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00401-019-02081-1","volume":"138","author":"J Chiang","year":"2019","unstructured":"Chiang, J. et al. A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathol. 138, 1091\u20131092 (2019).","journal-title":"Acta Neuropathol."},{"key":"2299_CR150","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1093\/hmg\/ddaa231","volume":"29","author":"M Saini","year":"2021","unstructured":"Saini, M., Jha, A. N., Tangri, R., Qudratullah, M. & Ali, S. MN1 overexpression with varying tumor grade is a promising predictor of survival of glioma patients. Hum. Mol. Genet. 29, 3532\u20133545 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"2299_CR151","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10014-019-00346-x","volume":"36","author":"R Mhatre","year":"2019","unstructured":"Mhatre, R. et al. MN1 rearrangement in astroblastoma: study of eight cases and review of literature. Brain Tumor Pathol. 36, 112\u2013120 (2019).","journal-title":"Brain Tumor Pathol."},{"key":"2299_CR152","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40478-019-0689-3","volume":"7","author":"NL Lehman","year":"2019","unstructured":"Lehman, N. L. et al. Genomic analysis demonstrates that histologically defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. Acta Neuropathol. Commun. 7, 42 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"2299_CR153","first-page":"1353","volume":"60","author":"LM Liau","year":"2000","unstructured":"Liau, L. M. et al. Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Res. 60, 1353\u20131360 (2000).","journal-title":"Cancer Res."},{"key":"2299_CR154","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s12032-011-0131-6","volume":"29","author":"M Wang","year":"2012","unstructured":"Wang, M., Li, G., Yin, J., Lin, T. & Zhang, J. Progranulin overexpression predicts overall survival in patients with glioblastoma. Med. Oncol. 29, 2423\u20132431 (2012).","journal-title":"Med. Oncol."},{"key":"2299_CR155","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/onc.2014.92","volume":"34","author":"I Bandey","year":"2015","unstructured":"Bandey, I., Chiou, S.-H., Huang, A.-P., Tsai, J.-C. & Tu, P. h. Progranulin promotes temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness. Oncogene 34, 1853\u20131864 (2015).","journal-title":"Oncogene"},{"key":"2299_CR156","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s12031-020-01598-5","volume":"70","author":"I-N Lee","year":"2020","unstructured":"Lee, I.-N. et al. Knockdown of amphiregulin triggers doxorubicin-induced autophagic and apoptotic death by regulating endoplasmic reticulum stress in glioblastoma cells. J. Mol. Neurosci. 70, 1461\u20131470 (2020).","journal-title":"J. Mol. Neurosci."},{"key":"2299_CR157","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.7150\/jca.29282","volume":"10","author":"G Steponaitis","year":"2019","unstructured":"Steponaitis, G. et al. Significance of Amphiregulin (AREG) for the outcome of low and high grade astrocytoma patients. J. Cancer 10, 1479\u20131488 (2019).","journal-title":"J. Cancer"},{"key":"2299_CR158","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/1538-7445.AM2015-2391","volume":"75","author":"B Desai","year":"2015","unstructured":"Desai, B., Rath, U., Segall, J. E. & Coniglio, S. J. Abstract 2391: microglia-stimulated glioblastoma cell invasion is dependent on the EGFR ligand amphiregulin. Cancer Res 75, 2391 (2015).","journal-title":"Cancer Res"},{"key":"2299_CR159","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3389\/fonc.2016.00222","volume":"6","author":"L Garros-Regulez","year":"2016","unstructured":"Garros-Regulez, L. et al. Targeting SOX2 as a therapeutic strategy in glioblastoma. Front. Oncol. 6, 222 (2016).","journal-title":"Front. Oncol."},{"key":"2299_CR160","first-page":"139","volume":"8","author":"L Annovazzi","year":"2011","unstructured":"Annovazzi, L., Mellai, M., Caldera, V., Valente, G. & Schiffer, D. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genom. Proteom. 8, 139\u2013147 (2011).","journal-title":"Cancer Genom. Proteom."},{"key":"2299_CR161","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1634\/stemcells.2008-0493","volume":"27","author":"RMR Gangemi","year":"2009","unstructured":"Gangemi, R. M. R. et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27, 40\u201348 (2009).","journal-title":"Stem Cells"},{"key":"2299_CR162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00710-4","volume":"7","author":"H Lopez-Bertoni","year":"2022","unstructured":"Lopez-Bertoni, H. et al. Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications. Signal Transduct. Target Ther. 7, 1\u201312 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2299_CR163","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1101\/gad.1596707","volume":"21","author":"FB Furnari","year":"2007","unstructured":"Furnari, F. B. et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21, 2683\u20132710 (2007).","journal-title":"Genes Dev."},{"key":"2299_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2015.07.148","volume":"465","author":"J Wang","year":"2015","unstructured":"Wang, J., Su, H., Zhao, H., Chen, Z. & To, S. T. Progress in the application of molecular biomarkers in gliomas. Biochem. Biophys. Res. Commun. 465, 1\u20134 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2299_CR165","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature11903","volume":"494","author":"TCGAR Network","year":"2013","unstructured":"Network, T. C. G. A. R. Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 494, 506 (2013).","journal-title":"Nature"},{"key":"2299_CR166","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/cancers10090297","volume":"10","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. The p53 pathway in glioblastoma. Cancers 10, 297 (2018).","journal-title":"Cancers"},{"key":"2299_CR167","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/onc.2010.614","volume":"30","author":"C Romagosa","year":"2011","unstructured":"Romagosa, C. et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 30, 2087\u20132097 (2011).","journal-title":"Oncogene"},{"key":"2299_CR168","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1006\/excr.1997.3824","volume":"237","author":"M Serrano","year":"1997","unstructured":"Serrano, M. The tumor suppressor protein p16INK4a. Exp. Cell Res. 237, 7\u201313 (1997).","journal-title":"Exp. Cell Res."},{"key":"2299_CR169","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/NEN.0000000000000188","volume":"74","author":"GF Reis","year":"2015","unstructured":"Reis, G. F. et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J. Neuropathol. Exp. Neurol. 74, 442\u2013452 (2015).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2299_CR170","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11060-020-03528-2","volume":"148","author":"VM Lu","year":"2020","unstructured":"Lu, V. M. et al. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. J. Neurooncol. 148, 221\u2013229 (2020).","journal-title":"J. Neurooncol."},{"key":"2299_CR171","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa, A. T. et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13, 84\u201388 (2007).","journal-title":"Nat. Med."},{"key":"2299_CR172","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jocn.2010.04.021","volume":"17","author":"JS Waldron","year":"2010","unstructured":"Waldron, J. S. et al. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. J. Clin. Neurosci. 17, 1543\u20131547 (2010).","journal-title":"J. Clin. Neurosci."},{"key":"2299_CR173","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ccell.2019.05.003","volume":"35","author":"P Chen","year":"2019","unstructured":"Chen, P. et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-Null glioma. Cancer Cell 35, 868\u2013884.e6 (2019).","journal-title":"Cancer Cell"},{"key":"2299_CR174","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178628","volume":"134","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. J. Clin. Investig. 134, e178628 (2024).","journal-title":"J. Clin. Investig."},{"key":"2299_CR175","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0600-4","volume":"16","author":"PR Prasetyanti","year":"2017","unstructured":"Prasetyanti, P. R. & Medema, J. P. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol. Cancer 16, 41 (2017).","journal-title":"Mol. Cancer"},{"key":"2299_CR176","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1215\/15228517-2007-016","volume":"9","author":"S Larjavaara","year":"2007","unstructured":"Larjavaara, S. et al. Incidence of gliomas by anatomic location. Neuro Oncol. 9, 319\u2013325 (2007).","journal-title":"Neuro Oncol."},{"key":"2299_CR177","first-page":"48","volume":"3","author":"A Bradshaw","year":"2016","unstructured":"Bradshaw, A. et al. Cancer stem cells in glioblastoma multiforme. Front. Surg. 3, 48 (2016).","journal-title":"Front. Surg."},{"key":"2299_CR178","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/cancers13040761","volume":"13","author":"AP Becker","year":"2021","unstructured":"Becker, A. P., Sells, B. E., Haque, S. J. & Chakravarti, A. Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology. Cancers 13, 761 (2021).","journal-title":"Cancers"},{"key":"2299_CR179","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/0008-5472.CAN-11-0153","volume":"71","author":"R Bonavia","year":"2011","unstructured":"Bonavia, R., Inda, M.-M., Cavenee, W. K. & Furnari, F. B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 71, 4055\u20134060 (2011).","journal-title":"Cancer Res."},{"key":"2299_CR180","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrc3261","volume":"12","author":"A Marusyk","year":"2012","unstructured":"Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 12, 323\u2013334 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2299_CR181","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.1239947","volume":"343","author":"BE Johnson","year":"2014","unstructured":"Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189\u2013193 (2014).","journal-title":"Science"},{"key":"2299_CR182","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.1114033109","volume":"109","author":"NJ Szerlip","year":"2012","unstructured":"Szerlip, N. J. et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. USA 109, 3041\u20133046 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2299_CR183","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/0008-5472.CAN-11-4069","volume":"72","author":"SE Little","year":"2012","unstructured":"Little, S. E. et al. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res. 72, 1614\u20131620 (2012).","journal-title":"Cancer Res."},{"key":"2299_CR184","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","volume":"20","author":"M Snuderl","year":"2011","unstructured":"Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810\u2013817 (2011).","journal-title":"Cancer Cell"},{"key":"2299_CR185","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/cancers12051232","volume":"12","author":"A Dominiak","year":"2020","unstructured":"Dominiak, A., Che\u0142stowska, B., Olejarz, W. & Nowicka, G. Communication in the cancer microenvironment as a target for therapeutic interventions. Cancers 12, 1232 (2020).","journal-title":"Cancers"},{"key":"2299_CR186","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3171\/2019.7.JNS191376","volume":"133","author":"AN Ibrahim","year":"2019","unstructured":"Ibrahim, A. N. et al. Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor. J. Neurosurg. 133, 1683\u20131694 (2019).","journal-title":"J. Neurosurg."},{"key":"2299_CR187","first-page":"65","volume":"62","author":"A \u0100boli\u0146\u0161","year":"2011","unstructured":"\u0100boli\u0146\u0161, A. et al. Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report. Pol. J. Pathol. 62, 65\u201368 (2011).","journal-title":"Pol. J. Pathol."},{"key":"2299_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-019-0108-5","volume":"5","author":"GDA Guardia","year":"2020","unstructured":"Guardia, G. D. A. et al. Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles. npj Genom. Med. 5, 1\u201312 (2020).","journal-title":"npj Genom. Med."},{"key":"2299_CR189","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/scrt166","volume":"4","author":"B Ortensi","year":"2013","unstructured":"Ortensi, B., Setti, M., Osti, D. & Pelicci, G. Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res. Ther. 4, 18 (2013).","journal-title":"Stem Cell Res. Ther."},{"key":"2299_CR190","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cell.2013.02.021","volume":"153","author":"L Cheng","year":"2013","unstructured":"Cheng, L. et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153, 139\u2013152 (2013).","journal-title":"Cell"},{"key":"2299_CR191","doi-asserted-by":"publisher","first-page":"e14845","DOI":"10.7554\/eLife.14845","volume":"5","author":"B Krusche","year":"2016","unstructured":"Krusche, B. et al. EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells. Elife 5, e14845 (2016).","journal-title":"Elife"},{"key":"2299_CR192","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature08712","volume":"463","author":"MS Carro","year":"2010","unstructured":"Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumors. Nature 463, 318\u2013325 (2010).","journal-title":"Nature"},{"key":"2299_CR193","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1158\/0008-5472.CAN-14-3790","volume":"75","author":"SU Ahmed","year":"2015","unstructured":"Ahmed, S. U. et al. Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Res. 75, 4416\u20134428 (2015).","journal-title":"Cancer Res."},{"key":"2299_CR194","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1158\/0008-5472.CAN-18-0569","volume":"78","author":"RD Carruthers","year":"2018","unstructured":"Carruthers, R. D. et al. Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells. Cancer Res 78, 5060\u20135071 (2018).","journal-title":"Cancer Res"},{"key":"2299_CR195","doi-asserted-by":"publisher","first-page":"1123853","DOI":"10.3389\/fimmu.2023.1123853","volume":"14","author":"C Lin","year":"2023","unstructured":"Lin, C., Wang, N. & Xu, C. Glioma-associated microglia\/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy. Front. Immunol. 14, 1123853 (2023).","journal-title":"Front. Immunol."},{"key":"2299_CR196","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/cells10030621","volume":"10","author":"K Biserova","year":"2021","unstructured":"Biserova, K., Jakovlevs, A., Uljanovs, R. & Strumfa, I. Cancer stem cells: significance in origin, pathogenesis and treatment of glioblastoma. Cells 10, 621 (2021).","journal-title":"Cells"},{"key":"2299_CR197","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","volume":"6","author":"BC Prager","year":"2020","unstructured":"Prager, B. C., Bhargava, S., Mahadev, V., Hubert, C. G. & Rich, J. N. Glioblastoma stem cells: driving resilience through chaos. Trends Cancer 6, 223\u2013235 (2020).","journal-title":"Trends Cancer"},{"key":"2299_CR198","first-page":"368","volume":"146","author":"E Hatva","year":"1995","unstructured":"Hatva, E. et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am. J. Pathol. 146, 368\u2013378 (1995).","journal-title":"Am. J. Pathol."},{"key":"2299_CR199","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/glia.440150313","volume":"15","author":"KH Plate","year":"1995","unstructured":"Plate, K. H. & Risau, W. Angiogenesis in malignant gliomas. Glia 15, 339\u2013347 (1995).","journal-title":"Glia"},{"key":"2299_CR200","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s007010170122","volume":"143","author":"Y Yao","year":"2001","unstructured":"Yao, Y. et al. Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir. 143, 159\u2013166 (2001).","journal-title":"Acta Neurochir."},{"key":"2299_CR201","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/0284186X.2014.951492","volume":"54","author":"L Sooman","year":"2015","unstructured":"Sooman, L. et al. FGF2 as a potential prognostic biomarker for proneural glioma patients. Acta Oncol.54, 385\u2013394 (2015).","journal-title":"Acta Oncol."},{"key":"2299_CR202","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-14-0834","volume":"20","author":"TT Batchelor","year":"2014","unstructured":"Batchelor, T. T., Reardon, D. A., de Groot, J. F., Wick, W. & Weller, M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin. Cancer Res. 20, 5612\u20135619 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR203","first-page":"383","volume":"7","author":"S Kanda","year":"1996","unstructured":"Kanda, S., Landgren, E., Ljungstr\u00f6m, M. & Claesson-Welsh, L. Fibroblast growth factor receptor 1-induced differentiation of endothelial cell line established from tsA58 large T transgenic mice. Cell Growth Differ. 7, 383\u2013395 (1996).","journal-title":"Cell Growth Differ."},{"key":"2299_CR204","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1215\/S1152851705000050","volume":"7","author":"R Abounader","year":"2005","unstructured":"Abounader, R. & Laterra, J. Scatter factor\/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 7, 436\u2013451 (2005).","journal-title":"Neuro Oncol."},{"key":"2299_CR205","first-page":"3871","volume":"37","author":"T Okuda","year":"2017","unstructured":"Okuda, T. et al. Efficacy of combination therapy with MET and VEGF inhibitors for MET-overexpressing glioblastoma. Anticancer Res. 37, 3871\u20133876 (2017).","journal-title":"Anticancer Res."},{"key":"2299_CR206","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1158\/0008-5472.CAN-09-4125","volume":"70","author":"MK Brunckhorst","year":"2010","unstructured":"Brunckhorst, M. K., Wang, H., Lu, R. & Yu, Q. Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res. 70, 7283\u20137293 (2010).","journal-title":"Cancer Res."},{"key":"2299_CR207","doi-asserted-by":"publisher","first-page":"39","DOI":"10.15252\/emmm.201505505","volume":"8","author":"A Scholz","year":"2016","unstructured":"Scholz, A. et al. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol. Med. 8, 39\u201357 (2016).","journal-title":"EMBO Mol. Med."},{"key":"2299_CR208","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ccr.2006.11.023","volume":"11","author":"A Bruna","year":"2007","unstructured":"Bruna, A. et al. High TGF\u03b2-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11, 147\u2013160 (2007).","journal-title":"Cancer Cell"},{"key":"2299_CR209","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/35036374","volume":"2","author":"G Bergers","year":"2000","unstructured":"Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737\u2013744 (2000).","journal-title":"Nat. Cell Biol."},{"key":"2299_CR210","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s12035-020-01892-8","volume":"57","author":"BK Ahir","year":"2020","unstructured":"Ahir, B. K., Engelhard, H. H. & Lakka, S. S. Tumor development and angiogenesis in adult brain tumor: glioblastoma. Mol. Neurobiol. 57, 2461\u20132478 (2020).","journal-title":"Mol. Neurobiol."},{"key":"2299_CR211","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12253-017-0310-7","volume":"25","author":"P Cj","year":"2019","unstructured":"Cj, P. et al. High LC3\/beclin expression correlates with poor survival in glioma: a definitive role for autophagy as evidenced by in vitro autophagic flux. Pathol. Oncol. Res. 25, 137\u2013148 (2019).","journal-title":"Pathol. Oncol. Res."},{"key":"2299_CR212","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1080\/15548627.2016.1190053","volume":"12","author":"N Gammoh","year":"2016","unstructured":"Gammoh, N. et al. Suppression of autophagy impedes glioblastoma development and induces senescence. Autophagy 12, 1431\u20131439 (2016).","journal-title":"Autophagy"},{"key":"2299_CR213","doi-asserted-by":"publisher","first-page":"208076","DOI":"10.1155\/2015\/208076","volume":"2015","author":"P Tini","year":"2015","unstructured":"Tini, P. et al. Combined epidermal growth factor receptor and beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma. Biomed. Res. Int. 2015, 208076 (2015).","journal-title":"Biomed. Res. Int."},{"key":"2299_CR214","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00587-w","volume":"18","author":"MH Pourhanifeh","year":"2020","unstructured":"Pourhanifeh, M. H. et al. Autophagy in cancers including brain tumors: role of MicroRNAs. Cell Commun. Signal. 18, 88 (2020).","journal-title":"Cell Commun. Signal."},{"key":"2299_CR215","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4161\/auto.5278","volume":"4","author":"MB Azad","year":"2008","unstructured":"Azad, M. B. et al. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy 4, 195\u2013204 (2008).","journal-title":"Autophagy"},{"key":"2299_CR216","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.molonc.2015.04.016","volume":"9","author":"M Catalano","year":"2015","unstructured":"Catalano, M. et al. Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. Mol. Oncol. 9, 1612\u20131625 (2015).","journal-title":"Mol. Oncol."},{"key":"2299_CR217","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13046-019-1287-8","volume":"38","author":"Z Wen","year":"2019","unstructured":"Wen, Z. et al. Knockdown ATG4C inhibits gliomas progression and promotes temozolomide chemosensitivity by suppressing autophagic flux. J. Exp. Clin. Cancer Res. 38, 298 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2299_CR218","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/onc.2012.111","volume":"32","author":"S Galavotti","year":"2013","unstructured":"Galavotti, S. et al. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 32, 699\u2013712 (2013).","journal-title":"Oncogene"},{"key":"2299_CR219","doi-asserted-by":"publisher","first-page":"9825","DOI":"10.3390\/ijms24129825","volume":"24","author":"L Zhang","year":"2021","unstructured":"Zhang, L., Fritah, S., Nazarov, P. V., Kaoma, T. & Dyck, E. V. Impact of IDH mutations, the 1p\/19q co-deletion and the G-CIMP status on alternative splicing in diffuse gliomas. Int. J. Mol. Sci. 24, 9825 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR220","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41416-020-1021-5","volume":"123","author":"DR Grimes","year":"2020","unstructured":"Grimes, D. R., Jansen, M., Macauley, R. J., Scott, J. G. & Basanta, D. Evidence for hypoxia increasing the tempo of evolution in glioblastoma. Br. J. Cancer 123, 1562\u20131569 (2020).","journal-title":"Br. J. Cancer"},{"key":"2299_CR221","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.153","volume":"3","author":"L Persano","year":"2012","unstructured":"Persano, L. et al. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1\u03b1 stability and MGMT expression. Cell Death Dis. 3, e412 (2012).","journal-title":"Cell Death Dis."},{"key":"2299_CR222","first-page":"22073","volume":"8","author":"Q Liu","year":"2015","unstructured":"Liu, Q. & Cao, P. Clinical and prognostic significance of HIF-1\u03b1 in glioma patients: a meta-analysis. Int. J. Clin. Exp. Med. 8, 22073\u201322083 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"2299_CR223","doi-asserted-by":"publisher","first-page":"12608","DOI":"10.3390\/ijms222212608","volume":"22","author":"M Dom\u00e8nech","year":"2021","unstructured":"Dom\u00e8nech, M., Hern\u00e1ndez, A., Plaja, A., Mart\u00ednez-Balibrea, E. & Bala\u00f1\u00e0, C. Hypoxia: the cornerstone of glioblastoma. Int. J. Mol. Sci. 22, 12608 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR224","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3109\/00207454.2013.789874","volume":"123","author":"J Reszec","year":"2013","unstructured":"Reszec, J., Rutkowski, R. & Chyczewski, L. The expression of hypoxia-inducible factor-1 in primary brain tumors. Int. J. Neurosci. 123, 657\u2013662 (2013).","journal-title":"Int. J. Neurosci."},{"key":"2299_CR225","first-page":"118733","volume":"1867","author":"A Bouthelier","year":"2020","unstructured":"Bouthelier, A. & Aragon\u00e9s, J. Role of the HIF oxygen sensing pathway in cell defense and proliferation through the control of amino acid metabolism. BBA- Mol. Cell. Res. 1867, 118733 (2020).","journal-title":"BBA- Mol. Cell. Res."},{"key":"2299_CR226","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1138-4","volume":"19","author":"X Li","year":"2020","unstructured":"Li, X., He, S. & Ma, B. Autophagy and autophagy-related proteins in cancer. Mol. Cancer 19, 12 (2020).","journal-title":"Mol. Cancer"},{"key":"2299_CR227","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","volume":"2","author":"L Schito","year":"2016","unstructured":"Schito, L. & Semenza, G. L. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer 2, 758\u2013770 (2016).","journal-title":"Trends Cancer"},{"key":"2299_CR228","doi-asserted-by":"publisher","first-page":"637454","DOI":"10.3389\/fcell.2021.637454","volume":"9","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. The roles of HIF-1\u03b1 in radiosensitivity and radiation-induced bystander effects under hypoxia. Front. Cell Dev. Biol. 9, 637454 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"2299_CR229","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/neuonc\/now258","volume":"19","author":"N Colwell","year":"2017","unstructured":"Colwell, N. et al. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro Oncol. 19, 887\u2013896 (2017).","journal-title":"Neuro Oncol."},{"key":"2299_CR230","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.yexcr.2016.04.011","volume":"343","author":"J-H Tang","year":"2016","unstructured":"Tang, J.-H. et al. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment. Exp. Cell Res. 343, 148\u2013158 (2016).","journal-title":"Exp. Cell Res."},{"key":"2299_CR231","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1084\/jem.20101470","volume":"208","author":"A Wolf","year":"2011","unstructured":"Wolf, A. et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med. 208, 313\u2013326 (2011).","journal-title":"J. Exp. Med."},{"key":"2299_CR232","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00906-9","volume":"8","author":"J-H Lee","year":"2017","unstructured":"Lee, J.-H. et al. Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. Nat. Commun. 8, 949 (2017).","journal-title":"Nat. Commun."},{"key":"2299_CR233","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101453","volume":"23","author":"J Sperry","year":"2020","unstructured":"Sperry, J. et al. Glioblastoma utilizes fatty acids and ketone bodies for growth allowing progression during ketogenic diet therapy. iScience 23, 101453 (2020).","journal-title":"iScience"},{"key":"2299_CR234","doi-asserted-by":"publisher","first-page":"ra82","DOI":"10.1126\/scisignal.2000446","volume":"2","author":"D Guo","year":"2009","unstructured":"Guo, D. et al. EGFR signaling through an Akt-SREBP-1 dependent, rapamycin-resistant pathway sensitizes glioblastomas to anti-lipogenic therapy. Sci. Signal 2, ra82 (2009).","journal-title":"Sci. Signal"},{"key":"2299_CR235","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3390\/ijms21061931","volume":"21","author":"FL Ricklefs","year":"2020","unstructured":"Ricklefs, F. L. et al. FASN is a biomarker enriched in malignant glioma-derived extracellular vesicles. Int. J. Mol. Sci. 21, 1931 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR236","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-19-0061","volume":"9","author":"RC Gimple","year":"2019","unstructured":"Gimple, R. C. et al. Glioma stem cell-specific superenhancer promotes polyunsaturated fatty-acid synthesis to support EGFR signaling. Cancer Discov. 9, 1248\u20131267 (2019).","journal-title":"Cancer Discov."},{"key":"2299_CR237","doi-asserted-by":"publisher","first-page":"289ra86","DOI":"10.1126\/scitranslmed.aaa8103","volume":"7","author":"SM Robert","year":"2015","unstructured":"Robert, S. M. et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci. Transl. Med. 7, 289ra86 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2299_CR238","doi-asserted-by":"publisher","first-page":"7986","DOI":"10.1158\/0008-5472.CAN-09-2266","volume":"69","author":"C Yang","year":"2009","unstructured":"Yang, C. et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 69, 7986\u20137993 (2009).","journal-title":"Cancer Res."},{"key":"2299_CR239","first-page":"vdab057","volume":"3","author":"A Cano-Galiano","year":"2021","unstructured":"Cano-Galiano, A. et al. Cystathionine-\u03b3-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas. Neurooncol. Adv. 3, vdab057 (2021).","journal-title":"Neurooncol. Adv."},{"key":"2299_CR240","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jneuroim.2014.06.021","volume":"274","author":"AC Carvalho da Fonseca","year":"2014","unstructured":"Carvalho da Fonseca, A. C. et al. Increased expression of stress inducible protein 1 in glioma-associated microglia\/macrophages. J. Neuroimmunol. 274, 71\u201377 (2014).","journal-title":"J. Neuroimmunol."},{"key":"2299_CR241","doi-asserted-by":"publisher","first-page":"121558","DOI":"10.1016\/j.lfs.2023.121558","volume":"320","author":"X Zhu","year":"2023","unstructured":"Zhu, X. et al. Interaction of tumor-associated microglia\/macrophages and cancer stem cells in glioma. Life Sci. 320, 121558 (2023).","journal-title":"Life Sci."},{"key":"2299_CR242","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/ijms21218412","volume":"21","author":"J Korbecki","year":"2020","unstructured":"Korbecki, J. et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. Int. J. Mol. Sci. 21, 8412 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR243","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","volume":"22","author":"MC Takenaka","year":"2019","unstructured":"Takenaka, M. C. et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat. Neurosci. 22, 729\u2013740 (2019).","journal-title":"Nat. Neurosci."},{"key":"2299_CR244","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","volume":"40","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M. et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell 40, 639\u2013655.e13 (2022).","journal-title":"Cancer Cell"},{"key":"2299_CR245","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s004010051093","volume":"98","author":"G Fossati","year":"1999","unstructured":"Fossati, G. et al. Neutrophil infiltration into human gliomas. Acta Neuropathol. 98, 349\u2013354 (1999).","journal-title":"Acta Neuropathol."},{"key":"2299_CR246","doi-asserted-by":"publisher","first-page":"154","DOI":"10.20892\/j.issn.2095-3941.2019.0353","volume":"17","author":"C Zha","year":"2020","unstructured":"Zha, C. et al. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1\/RAGE\/IL-8 axis. Cancer Biol. Med. 17, 154\u2013168 (2020).","journal-title":"Cancer Biol. Med."},{"key":"2299_CR247","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ccell.2016.06.001","volume":"30","author":"S Singhal","year":"2016","unstructured":"Singhal, S. et al. Origin and role of a subset of tumor-associated neutrophils with antigen presenting cell features (Hybrid TANs) in early-stage human lung cancer. Cancer Cell 30, 120\u2013135 (2016).","journal-title":"Cancer Cell"},{"key":"2299_CR248","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/neuonc\/now034","volume":"18","author":"PR Gielen","year":"2016","unstructured":"Gielen, P. R. et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8\/9 and arginase and suppress T cell function. Neuro Oncol. 18, 1253\u20131264 (2016).","journal-title":"Neuro Oncol."},{"key":"2299_CR249","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3389\/fimmu.2020.00737","volume":"11","author":"Y Mi","year":"2020","unstructured":"Mi, Y. et al. The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment. Front. Immunol. 11, 737 (2020).","journal-title":"Front. Immunol."},{"key":"2299_CR250","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo, C. A. et al. HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207, 2439\u20132453 (2010).","journal-title":"J. Exp. Med."},{"key":"2299_CR251","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","volume":"109","author":"PC Rodriguez","year":"2007","unstructured":"Rodriguez, P. C., Quiceno, D. G. & Ochoa, A. C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109, 1568\u20131573 (2007).","journal-title":"Blood"},{"key":"2299_CR252","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","volume":"184","author":"ND Mathewson","year":"2021","unstructured":"Mathewson, N. D. et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 184, 1281\u20131298.e26 (2021).","journal-title":"Cell"},{"key":"2299_CR253","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1158\/1078-0432.CCR-10-2557","volume":"17","author":"J Lohr","year":"2011","unstructured":"Lohr, J. et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-\u03b2. Clin. Cancer Res. 17, 4296\u20134308 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR254","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.coi.2010.02.005","volume":"22","author":"PS Kim","year":"2010","unstructured":"Kim, P. S. & Ahmed, R. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22, 223\u2013230 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"2299_CR255","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547\u2013562 (2018).","journal-title":"Cancer Cell"},{"key":"2299_CR256","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","volume":"37","author":"S Guedan","year":"2019","unstructured":"Guedan, S., Ruella, M. & June, C. H. Emerging cellular therapies for cancer. Annu. Rev. Immunol. 37, 145\u2013171 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"2299_CR257","doi-asserted-by":"publisher","first-page":"585616","DOI":"10.3389\/fimmu.2020.585616","volume":"11","author":"T Daubon","year":"2020","unstructured":"Daubon, T., Hemadou, A., Romero Garmendia, I. & Saleh, M. Glioblastoma immune landscape and the potential of new immunotherapies. Front. Immunol. 11, 585616 (2020).","journal-title":"Front. Immunol."},{"key":"2299_CR258","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","volume":"129","author":"JS Yi","year":"2010","unstructured":"Yi, J. S., Cox, M. A. & Zajac, A. J. T-cell exhaustion: characteristics, causes and conversion. Immunology 129, 474\u2013481 (2010).","journal-title":"Immunology"},{"key":"2299_CR259","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.4049\/jimmunol.1002650","volume":"187","author":"Y-J Kim","year":"2011","unstructured":"Kim, Y.-J., Park, S.-J. & Broxmeyer, H. E. Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction. J. Immunol. 187, 2291\u20132301 (2011).","journal-title":"J. Immunol."},{"key":"2299_CR260","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00401-021-02401-4","volume":"143","author":"SM Markwell","year":"2022","unstructured":"Markwell, S. M., Ross, J. L., Olson, C. L. & Brat, D. J. Necrotic reshaping of the glioma microenvironment drives disease progression. Acta Neuropathol. 143, 291\u2013310 (2022).","journal-title":"Acta Neuropathol."},{"key":"2299_CR261","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J. Immunol. 164, 6166\u20136173 (2000).","journal-title":"J. Immunol."},{"key":"2299_CR262","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski, N. et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 18, 557\u2013564 (2016).","journal-title":"Neuro Oncol."},{"key":"2299_CR263","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15129-8","volume":"11","author":"CA von Roemeling","year":"2020","unstructured":"von Roemeling, C. A. et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat. Commun. 11, 1508 (2020).","journal-title":"Nat. Commun."},{"key":"2299_CR264","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1615\/CritRevOncog.v17.i1.60","volume":"17","author":"K Sheppard","year":"2012","unstructured":"Sheppard, K., Kinross, K. M., Solomon, B., Pearson, R. B. & Phillips, W. A. Targeting PI3 kinase\/AKT\/mTOR signaling in cancer. Crit. Rev. Oncog. 17, 69\u201395 (2012).","journal-title":"Crit. Rev. Oncog."},{"key":"2299_CR265","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12094-013-1109-y","volume":"16","author":"M Mendiburu-Eli\u00e7abe","year":"2014","unstructured":"Mendiburu-Eli\u00e7abe, M., Gil-Ranedo, J. & Izquierdo, M. Efficacy of rapamycin against glioblastoma cancer stem cells. Clin. Transl. Oncol. 16, 495\u2013502 (2014).","journal-title":"Clin. Transl. Oncol."},{"key":"2299_CR266","doi-asserted-by":"publisher","first-page":"10314","DOI":"10.1073\/pnas.171076798","volume":"98","author":"MS Neshat","year":"2001","unstructured":"Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc. Natl Acad. Sci. USA 98, 10314\u201310319 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2299_CR267","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.cdd.4400978","volume":"9","author":"M Castedo","year":"2002","unstructured":"Castedo, M., Ferri, K. F. & Kroemer, G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ. 9, 99\u2013100 (2002).","journal-title":"Cell Death Differ."},{"key":"2299_CR268","doi-asserted-by":"publisher","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-07-2223","volume":"67","author":"J Masri","year":"2007","unstructured":"Masri, J. et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 67, 11712\u201311720 (2007).","journal-title":"Cancer Res."},{"key":"2299_CR269","doi-asserted-by":"publisher","first-page":"ra4","DOI":"10.1126\/scisignal.2000014","volume":"2","author":"Q-W Fan","year":"2009","unstructured":"Fan, Q.-W. et al. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci. Signal 2, ra4 (2009).","journal-title":"Sci. Signal"},{"key":"2299_CR270","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/neuonc\/nov265","volume":"18","author":"KE Cahill","year":"2016","unstructured":"Cahill, K. E., Morshed, R. A. & Yamini, B. Nuclear factor-\u03baB in glioblastoma: insights into regulators and targeted therapy. Neuro Oncol. 18, 329\u2013339 (2016).","journal-title":"Neuro Oncol."},{"key":"2299_CR271","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1158\/0008-5472.CAN-15-0884","volume":"76","author":"N Ohtsu","year":"2016","unstructured":"Ohtsu, N. et al. Eva1 maintains the stem-like character of glioblastoma-initiating cells by activating the noncanonical NF-\u03baB signaling pathway. Cancer Res. 76, 171\u2013181 (2016).","journal-title":"Cancer Res."},{"key":"2299_CR272","doi-asserted-by":"publisher","first-page":"9535","DOI":"10.1158\/0008-5472.CAN-06-0418","volume":"66","author":"NL Tran","year":"2006","unstructured":"Tran, N. L. et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res. 66, 9535\u20139542 (2006).","journal-title":"Cancer Res."},{"key":"2299_CR273","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1242\/jcs.00286","volume":"116","author":"S Kiriakidis","year":"2003","unstructured":"Kiriakidis, S. et al. VEGF expression in human macrophages is NF-kappaB dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J. Cell Sci. 116, 665\u2013674 (2003).","journal-title":"J. Cell Sci."},{"key":"2299_CR274","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.molcel.2012.09.028","volume":"48","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. EGFR-induced and PKC\u03b5 monoubiquitylation-dependent NF-\u03baB activation upregulates PKM2 expression and promotes tumorigenesis. Mol. Cell 48, 771\u2013784 (2012).","journal-title":"Mol. Cell"},{"key":"2299_CR275","doi-asserted-by":"publisher","first-page":"8952","DOI":"10.1158\/0008-5472.CAN-06-3820","volume":"67","author":"I Lavon","year":"2007","unstructured":"Lavon, I. et al. Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res. 67, 8952\u20138959 (2007).","journal-title":"Cancer Res."},{"key":"2299_CR276","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/cancers13030437","volume":"13","author":"A Ou","year":"2021","unstructured":"Ou, A., Ott, M., Fang, D. & Heimberger, A. B. The role and therapeutic targeting of JAK\/STAT signaling in glioblastoma. Cancers 13, 437 (2021).","journal-title":"Cancers"},{"key":"2299_CR277","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccr.2011.03.004","volume":"19","author":"OA Guryanova","year":"2011","unstructured":"Guryanova, O. A. et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 19, 498\u2013511 (2011).","journal-title":"Cancer Cell"},{"key":"2299_CR278","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1227\/NEU.0b013e3181f1c0cd","volume":"67","author":"S-H Kang","year":"2010","unstructured":"Kang, S.-H. et al. Activated STAT3 regulates hypoxia-induced angiogenesis and cell migration in human glioblastoma. Neurosurgery 67, 1386\u20131395 (2010). discussion 1395.","journal-title":"Neurosurgery"},{"key":"2299_CR279","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1093\/neuonc\/nou046","volume":"16","author":"Q Zheng","year":"2014","unstructured":"Zheng, Q. et al. JAK2\/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII\/JAK2\/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. Neuro Oncol. 16, 1229\u20131243 (2014).","journal-title":"Neuro Oncol."},{"key":"2299_CR280","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/cells8111398","volume":"8","author":"C Piperi","year":"2019","unstructured":"Piperi, C., Papavassiliou, K. A. & Papavassiliou, A. G. Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells 8, 1398 (2019).","journal-title":"Cells"},{"key":"2299_CR281","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-11-0801","volume":"11","author":"S Kohsaka","year":"2012","unstructured":"Kohsaka, S. et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol. Cancer Ther. 11, 1289\u20131299 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2299_CR282","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1158\/0008-5472.CAN-14-2800","volume":"75","author":"A-H Gong","year":"2015","unstructured":"Gong, A.-H. et al. FoxM1 drives a feed-forward STAT3-activation signaling loop that promotes the self-renewal and tumorigenicity of glioblastoma stem-like cells. Cancer Res 75, 2337\u20132348 (2015).","journal-title":"Cancer Res"},{"key":"2299_CR283","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1101\/gad.1606508","volume":"22","author":"N de la Iglesia","year":"2008","unstructured":"de la Iglesia, N. et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 22, 449\u2013462 (2008).","journal-title":"Genes Dev."},{"key":"2299_CR284","doi-asserted-by":"crossref","unstructured":"McCord, M., Mukouyama, Y., Gilbert, M. R. & Jackson, S. Targeting WNT signaling for multifaceted glioblastoma therapy. Front. Cell. Neurosci. 11, (2017).","DOI":"10.3389\/fncel.2017.00318"},{"key":"2299_CR285","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/ijc.24981","volume":"126","author":"S G\u00f6tze","year":"2010","unstructured":"G\u00f6tze, S., Wolter, M., Reifenberger, G., M\u00fcller, O. & Sievers, S. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int. J. Cancer 126, 2584\u20132593 (2010).","journal-title":"Int. J. Cancer"},{"key":"2299_CR286","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/cgt.2008.78","volume":"16","author":"P Pu","year":"2009","unstructured":"Pu, P. et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 16, 351\u2013361 (2009).","journal-title":"Cancer Gene Ther."},{"key":"2299_CR287","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/bjc.2015.242","volume":"113","author":"C Maris","year":"2015","unstructured":"Maris, C. et al. IGF-IR: a new prognostic biomarker for human glioblastoma. Br. J. Cancer 113, 729\u2013737 (2015).","journal-title":"Br. J. Cancer"},{"key":"2299_CR288","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/neuonc\/nop008","volume":"12","author":"S Yin","year":"2010","unstructured":"Yin, S. et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol. 12, 19\u201327 (2010).","journal-title":"Neuro Oncol."},{"key":"2299_CR289","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/neuonc\/nou344","volume":"17","author":"M Zamykal","year":"2015","unstructured":"Zamykal, M. et al. Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms. Neuro Oncol. 17, 1076\u20131085 (2015).","journal-title":"Neuro Oncol."},{"key":"2299_CR290","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clineuro.2015.01.018","volume":"131","author":"Z Xing","year":"2015","unstructured":"Xing, Z., Sun, L. & Guo, W. Elevated expression of Notch-1 and EGFR induced apoptosis in glioblastoma multiforme patients. Clin. Neurol. Neurosurg. 131, 54\u201358 (2015).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"2299_CR291","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.65","volume":"3","author":"JS Tchorz","year":"2012","unstructured":"Tchorz, J. S. et al. Constitutive Notch2 signaling in neural stem cells promotes tumorigenic features and astroglial lineage entry. Cell Death Dis. 3, e325 (2012).","journal-title":"Cell Death Dis."},{"key":"2299_CR292","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/neuonc\/not168","volume":"16","author":"P Dell\u2019albani","year":"2014","unstructured":"Dell\u2019albani, P. et al. Differential patterns of NOTCH1-4 receptor expression are markers of glioma cell differentiation. Neuro Oncol. 16, 204\u2013216 (2014).","journal-title":"Neuro Oncol."},{"key":"2299_CR293","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/cdd.2011.95","volume":"19","author":"L Qiang","year":"2012","unstructured":"Qiang, L. et al. HIF-1\u03b1 is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ. 19, 284\u2013294 (2012).","journal-title":"Cell Death Differ."},{"key":"2299_CR294","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3171\/2015.11.JNS15432","volume":"126","author":"W Cheng","year":"2017","unstructured":"Cheng, W. et al. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. J. Neurosurg. 126, 249\u2013259 (2017).","journal-title":"J. Neurosurg."},{"key":"2299_CR295","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/0008-5472.CAN-13-1597","volume":"74","author":"H-M Jeon","year":"2014","unstructured":"Jeon, H.-M. et al. Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression. Cancer Res. 74, 4482\u20134492 (2014).","journal-title":"Cancer Res."},{"key":"2299_CR296","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0119-z","volume":"9","author":"L Hai","year":"2018","unstructured":"Hai, L. et al. Notch1 is a prognostic factor that is distinctly activated in the classical and proneural subtype of glioblastoma and that promotes glioma cell survival via the NF-\u03baB(p65) pathway. Cell Death Dis. 9, 158 (2018).","journal-title":"Cell Death Dis."},{"key":"2299_CR297","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3390\/cells9092114","volume":"9","author":"D Doheny","year":"2020","unstructured":"Doheny, D., Manore, S. G., Wong, G. L. & Lo, H.-W. Hedgehog signaling and truncated GLI1 in cancer. Cells 9, 2114 (2020).","journal-title":"Cells"},{"key":"2299_CR298","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canlet.2013.09.014","volume":"343","author":"H Zhu","year":"2014","unstructured":"Zhu, H., Carpenter, R. L., Han, W. & Lo, H.-W. The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth. Cancer Lett. 343, 51\u201361 (2014).","journal-title":"Cancer Lett."},{"key":"2299_CR299","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1158\/0008-5472.CAN-17-2933","volume":"78","author":"TK Rimkus","year":"2018","unstructured":"Rimkus, T. K. et al. Truncated glioma-associated oncogene homolog 1 (tGLI1) mediates mesenchymal glioblastoma via transcriptional activation of CD44. Cancer Res 78, 2589\u20132600 (2018).","journal-title":"Cancer Res"},{"key":"2299_CR300","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-017-0491-x","volume":"17","author":"K Wang","year":"2017","unstructured":"Wang, K. et al. Hedgehog\/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma. Cancer Cell Int. 17, 117 (2017).","journal-title":"Cancer Cell Int."},{"key":"2299_CR301","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc3398","volume":"13","author":"SAF Morad","year":"2013","unstructured":"Morad, S. A. F. & Cabot, M. C. Ceramide-orchestrated signaling in cancer cells. Nat. Rev. Cancer 13, 51\u201365 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"2299_CR302","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/pharmaceutics10020045","volume":"10","author":"HS Nguyen","year":"2018","unstructured":"Nguyen, H. S., Awad, A. J., Shabani, S. & Doan, N. Molecular targeting of acid ceramidase in glioblastoma: a review of its role, potential treatment, and challenges. Pharmaceutics 10, 45 (2018).","journal-title":"Pharmaceutics"},{"key":"2299_CR303","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1101\/gad.176800.111","volume":"25","author":"KPL Bhat","year":"2011","unstructured":"Bhat, K. P. L. et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 25, 2594\u20132609 (2011).","journal-title":"Genes Dev."},{"key":"2299_CR304","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-20-0018","volume":"27","author":"K Vigneswaran","year":"2021","unstructured":"Vigneswaran, K. et al. YAP\/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma. Clin. Cancer Res. 27, 1553\u20131569 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR305","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1096\/fj.201600550R","volume":"30","author":"L Selagea","year":"2016","unstructured":"Selagea, L. et al. EGFR and C\/EBP-\u03b2 oncogenic signaling is bidirectional in human glioma and varies with the C\/EBP-\u03b2 isoform. FASEB J. 30, 4098\u20134108 (2016).","journal-title":"FASEB J."},{"key":"2299_CR306","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3389\/fimmu.2020.00657","volume":"11","author":"T Kudo","year":"2020","unstructured":"Kudo, T. et al. Constitutive expression of the immunosuppressive tryptophan dioxygenase TDO2 in glioblastoma is driven by the transcription factor C\/EBP\u03b2. Front. Immunol. 11, 657 (2020).","journal-title":"Front. Immunol."},{"key":"2299_CR307","doi-asserted-by":"publisher","first-page":"101578","DOI":"10.1016\/j.redox.2020.101578","volume":"34","author":"K Lei","year":"2020","unstructured":"Lei, K. et al. C\/EBP\u03b2 mediates NQO1 and GSTP1 anti-oxidative reductases expression in glioblastoma, promoting brain tumor proliferation. Redox Biol. 34, 101578 (2020).","journal-title":"Redox Biol."},{"key":"2299_CR308","doi-asserted-by":"publisher","first-page":"E4055","DOI":"10.1073\/pnas.1501967112","volume":"112","author":"D Kozono","year":"2015","unstructured":"Kozono, D. et al. Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. Proc. Natl. Acad. Sci. USA 112, E4055\u2013E4064 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2299_CR309","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13046-019-1078-2","volume":"38","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma. J. Exp. Clin. Cancer Res. 38, 99 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2299_CR310","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-15-2274","volume":"22","author":"K Tateishi","year":"2016","unstructured":"Tateishi, K. et al. Myc-driven glycolysis is a therapeutic target in glioblastoma. Clin. Cancer Res. 22, 4452\u20134465 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR311","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/biomedicines9040381","volume":"9","author":"N Geribaldi-Dold\u00e1n","year":"2021","unstructured":"Geribaldi-Dold\u00e1n, N. et al. Targeting protein kinase c in glioblastoma treatment. Biomedicines 9, 381 (2021).","journal-title":"Biomedicines"},{"key":"2299_CR312","doi-asserted-by":"publisher","first-page":"109819","DOI":"10.1016\/j.cellsig.2020.109819","volume":"77","author":"A Dey","year":"2021","unstructured":"Dey, A., Islam, S. M. A., Patel, R. & Acevedo-Duncan, M. The interruption of atypical PKC signaling and Temozolomide combination therapy against glioblastoma. Cell. Signal. 77, 109819 (2021).","journal-title":"Cell. Signal."},{"key":"2299_CR313","doi-asserted-by":"publisher","first-page":"110054","DOI":"10.1016\/j.celrep.2021.110054","volume":"37","author":"RS Kenchappa","year":"2021","unstructured":"Kenchappa, R. S. et al. Protein kinase C\u03b9 and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. Cell Rep. 37, 110054 (2021).","journal-title":"Cell Rep."},{"key":"2299_CR314","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264\u20131272 (2013).","journal-title":"Nat. Med."},{"key":"2299_CR315","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile, M. A. et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5, 53 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"2299_CR316","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326\u2013341 (2017).","journal-title":"Cancer Cell"},{"key":"2299_CR317","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H. & Riley, J. L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945\u2013954 (2004).","journal-title":"J. Immunol."},{"key":"2299_CR318","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cells10020265","volume":"10","author":"B Majc","year":"2021","unstructured":"Majc, B., Novak, M., Kopitar-Jerala, N., Jewett, A. & Breznik, B. Immunotherapy of glioblastoma: current strategies and challenges in tumor model development. Cells 10, 265 (2021).","journal-title":"Cells"},{"key":"2299_CR319","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","volume":"19","author":"CJ David","year":"2018","unstructured":"David, C. J. & Massagu\u00e9, J. Contextual determinants of TGF\u03b2 action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419\u2013435 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2299_CR320","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022061","volume":"8","author":"A Hata","year":"2016","unstructured":"Hata, A. & Chen, Y.-G. TGF-\u03b2 signaling from receptors to smads. Cold Spring Harb. Perspect. Biol. 8, a022061 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2299_CR321","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"2299_CR322","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/ijms19051294","volume":"19","author":"L Caja","year":"2018","unstructured":"Caja, L. et al. TGF-\u03b2 and the tissue microenvironment: relevance in fibrosis and cancer. Int. J. Mol. Sci. 19, 1294 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR323","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck, R., Turley, S. J. & Akhurst, R. J. TGF\u03b2 biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2299_CR324","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","volume":"19","author":"L Antonioli","year":"2013","unstructured":"Antonioli, L., Pacher, P., Vizi, E. S. & Hask\u00f3, G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19, 355\u2013367 (2013).","journal-title":"Trends Mol. Med."},{"key":"2299_CR325","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1111\/j.1365-2567.2009.03075.x","volume":"128","author":"C Linnemann","year":"2009","unstructured":"Linnemann, C. et al. Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signaling. Immunology 128, e728\u2013e737 (2009).","journal-title":"Immunology"},{"key":"2299_CR326","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young, A. et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30, 391\u2013403 (2016).","journal-title":"Cancer Cell"},{"key":"2299_CR327","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","volume":"34","author":"DH Munn","year":"2013","unstructured":"Munn, D. H. & Mellor, A. L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34, 137\u2013143 (2013).","journal-title":"Trends Immunol."},{"key":"2299_CR328","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","volume":"18","author":"DA Wainwright","year":"2012","unstructured":"Wainwright, D. A. et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18, 6110\u20136121 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR329","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten, M., Nollen, E. A. A., R\u00f6hrig, U. F., Fallarino, F. & Opitz, C. A. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat. Rev. Drug Discov. 18, 379\u2013401 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2299_CR330","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197\u2013203 (2011).","journal-title":"Nature"},{"key":"2299_CR331","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1158\/1078-0432.CCR-17-3573","volume":"24","author":"E Ladomersky","year":"2018","unstructured":"Ladomersky, E. et al. IDO1 Inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin. Cancer Res. 24, 2559\u20132573 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR332","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1227\/01.neu.0000318159.21731.cf","volume":"62","author":"N Sanai","year":"2008","unstructured":"Sanai, N. & Berger, M. S. Glioma extent of resection and its impact on patient outcome. Neurosurgery 62, 753\u2013764 (2008). discussion 264-266.","journal-title":"Neurosurgery"},{"key":"2299_CR333","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/lsm.22933","volume":"50","author":"H Stepp","year":"2018","unstructured":"Stepp, H. & Stummer, W. 5-ALA in the management of malignant glioma. Lasers Surg. Med. 50, 399\u2013419 (2018).","journal-title":"Lasers Surg. Med."},{"key":"2299_CR334","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fonc.2019.00620","volume":"9","author":"S Gandhi","year":"2019","unstructured":"Gandhi, S. et al. Survival outcomes among patients with high-grade glioma treated with 5-aminolevulinic acid-guided surgery: a systematic review and meta-analysis. Front. Oncol. 9, 620 (2019).","journal-title":"Front. Oncol."},{"key":"2299_CR335","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11060-018-03061-3","volume":"141","author":"SA Haider","year":"2019","unstructured":"Haider, S. A., Lim, S., Kalkanis, S. N. & Lee, I. Y. The impact of 5-aminolevulinic acid on extent of resection in newly diagnosed high grade gliomas: a systematic review and single institutional experience. J. Neurooncol. 141, 507\u2013515 (2019).","journal-title":"J. Neurooncol."},{"key":"2299_CR336","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown, P. D. et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicenter, randomized, controlled, phase 3 trial. Lancet Oncol. 18, 1049\u20131060 (2017).","journal-title":"Lancet Oncol."},{"key":"2299_CR337","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3389\/fonc.2018.00342","volume":"8","author":"EM Marchan","year":"2018","unstructured":"Marchan, E. M. et al. Postoperative cavity stereotactic radiosurgery for brain metastases. Front. Oncol. 8, 342 (2018).","journal-title":"Front. Oncol."},{"key":"2299_CR338","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1016\/j.wneu.2019.03.193","volume":"127","author":"S-AL Morris","year":"2019","unstructured":"Morris, S.-A. L. et al. Gamma knife stereotactic radiosurgery in combination with bevacizumab for recurrent glioblastoma. World Neurosurg. 127, e523\u2013e533 (2019).","journal-title":"World Neurosurg."},{"key":"2299_CR339","first-page":"vdab185","volume":"4","author":"DJ Gessler","year":"2021","unstructured":"Gessler, D. J. et al. GammaTile\u00ae brachytherapy in the treatment of recurrent glioblastomas. Neurooncol. Adv. 4, vdab185 (2021).","journal-title":"Neurooncol. Adv."},{"key":"2299_CR340","doi-asserted-by":"publisher","first-page":"153303382412490","DOI":"10.1177\/15330338241249026","volume":"23","author":"A Morello","year":"2024","unstructured":"Morello, A. et al. Laser Interstitial Thermotherapy (LITT) in recurrent glioblastoma: what window of opportunity for this treatment?. Technol. Cancer Res. Treat. 23, 15330338241249026 (2024).","journal-title":"Technol. Cancer Res. Treat."},{"key":"2299_CR341","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/neuros\/nyy375","volume":"84","author":"AA Kamath","year":"2019","unstructured":"Kamath, A. A. et al. Glioblastoma treated with magnetic resonance imaging-guided laser interstitial thermal therapy: safety, efficacy, and outcomes. Neurosurgery 84, 836\u2013843 (2019).","journal-title":"Neurosurgery"},{"key":"2299_CR342","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/cam4.266","volume":"3","author":"AM Mohammadi","year":"2014","unstructured":"Mohammadi, A. M. et al. The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study. Cancer Med. 3, 971\u2013979 (2014).","journal-title":"Cancer Med."},{"key":"2299_CR343","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S1470-2045(24)00585-0","volume":"25","author":"S Vora","year":"2024","unstructured":"Vora, S. et al. Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial. Lancet Oncol. 25, 1625\u20131634 (2024).","journal-title":"Lancet Oncol."},{"key":"2299_CR344","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41582-020-00418-z","volume":"17","author":"Y Meng","year":"2021","unstructured":"Meng, Y., Hynynen, K. & Lipsman, N. Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat. Rev. Neurol. 17, 7\u201322 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"2299_CR345","doi-asserted-by":"publisher","first-page":"903059","DOI":"10.3389\/fonc.2022.903059","volume":"12","author":"R Mungur","year":"2022","unstructured":"Mungur, R. et al. Low-intensity focused ultrasound technique in glioblastoma multiforme treatment. Front. Oncol. 12, 903059 (2022).","journal-title":"Front. Oncol."},{"key":"2299_CR346","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.nano.2018.01.021","volume":"14","author":"D Coluccia","year":"2018","unstructured":"Coluccia, D. et al. Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound. Nanomedicine 14, 1137\u20131148 (2018).","journal-title":"Nanomedicine"},{"key":"2299_CR347","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.7150\/thno.35892","volume":"9","author":"N McDannold","year":"2019","unstructured":"McDannold, N. et al. Acoustic feedback enables safe and reliable carboplatin delivery across the blood\u2012brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model. Theranostics 9, 6284\u20136299 (2019).","journal-title":"Theranostics"},{"key":"2299_CR348","doi-asserted-by":"publisher","first-page":"E8717","DOI":"10.1073\/pnas.1807105115","volume":"115","author":"CD Arvanitis","year":"2018","unstructured":"Arvanitis, C. D. et al. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood\u2013tumor barrier disruption. Proc. Natl. Acad. Sci. USA 115, E8717\u2013E8726 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2299_CR349","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ijrobp.2020.12.019","volume":"110","author":"H-J Wei","year":"2021","unstructured":"Wei, H.-J. et al. Focused ultrasound-mediated blood\u2012brain barrier opening increases delivery and efficacy of etoposide for glioblastoma treatment. Int. J. Radiat. Oncol. Biol. Phys. 110, 539\u2013550 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2299_CR350","doi-asserted-by":"publisher","first-page":"2004381","DOI":"10.1002\/advs.202004381","volume":"8","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Neutrophil delivered hollow titania covered persistent luminescent nanosensitizer for ultrosound augmented chemo\/immuno glioblastoma therapy. Adv. Sci. 8, 2004381 (2021).","journal-title":"Adv. Sci."},{"key":"2299_CR351","doi-asserted-by":"publisher","first-page":"1700474","DOI":"10.1002\/advs.201700474","volume":"5","author":"M Wu","year":"2018","unstructured":"Wu, M. et al. Focused ultrasound-augmented delivery of biodegradable multifunctional nanoplatforms for imaging-guided brain tumor treatment. Adv. Sci. 5, 1700474 (2018).","journal-title":"Adv. Sci."},{"key":"2299_CR352","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1111\/jcmm.13695","volume":"22","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Mechanisms of enhanced antiglioma efficacy of polysorbate 80-modified paclitaxel-loaded PLGA nanoparticles by focused ultrasound. J. Cell Mol. Med. 22, 4171\u20134182 (2018).","journal-title":"J. Cell Mol. Med."},{"key":"2299_CR353","first-page":"426","volume":"8","author":"O Regev","year":"2021","unstructured":"Regev, O., Merkin, V., Blumenthal, D. T., Melamed, I. & Kaisman-Elbaz, T. Tumor-treating fields for the treatment of glioblastoma: a systematic review and meta-analysis. Neurooncol. Pract. 8, 426\u2013440 (2021).","journal-title":"Neurooncol. Pract."},{"key":"2299_CR354","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp, R. et al. NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomized phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192\u20132202 (2012).","journal-title":"Eur. J. Cancer"},{"key":"2299_CR355","first-page":"vdae121","volume":"6","author":"J Ma","year":"2024","unstructured":"Ma, J. et al. Directionally non-rotating electric field therapy delivered through implanted electrodes as a glioblastoma treatment platform: a proof-of-principle study. Neurooncol. Adv. 6, vdae121 (2024).","journal-title":"Neurooncol. Adv."},{"key":"2299_CR356","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/curroncol31070296","volume":"31","author":"M Jezierza\u0144ski","year":"2024","unstructured":"Jezierza\u0144ski, M. et al. Temozolomide (TMZ) in the treatment of glioblastoma multiforme\u2014a literature review and clinical outcomes. Curr. Oncol. 31, 3994\u20134002 (2024).","journal-title":"Curr. Oncol."},{"key":"2299_CR357","first-page":"17","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh, N., Miner, A., Hennis, L. & Mittal, S. Mechanisms of temozolomide resistance in glioblastoma\u2014a comprehensive review. Cancer Drug Resist 4, 17\u201343 (2021).","journal-title":"Cancer Drug Resist"},{"key":"2299_CR358","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1158\/1078-0432.CCR-23-0673","volume":"29","author":"B Lal","year":"2023","unstructured":"Lal, B. et al. Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma. Clin. Cancer Res. 29, 4209\u20134218 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR359","first-page":"vdad102","volume":"5","author":"O Kim","year":"2023","unstructured":"Kim, O. et al. Combined inhibition of topoisomerase I and poly(ADP-ribose) polymerase: a synergistic therapeutic strategy for glioblastoma with phosphatase and tensin homolog deficiency. Neurooncol. Adv. 5, vdad102 (2023).","journal-title":"Neurooncol. Adv."},{"key":"2299_CR360","doi-asserted-by":"publisher","first-page":"e13636","DOI":"10.1200\/JCO.2024.42.16_suppl.e13636","volume":"42","author":"J Joseph-Thomas","year":"2024","unstructured":"Joseph-Thomas, J. et al. A prospective study comparing AI-based clinical trial eligibility screening with traditional EMR-based screening. J. Clin. Oncol. 42, e13636\u2013e13636 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2299_CR361","doi-asserted-by":"publisher","first-page":"TPS2096","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2096","volume":"42","author":"JM Sepulveda","year":"2024","unstructured":"Sepulveda, J. M. et al. Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: phase Ib\/II CAN-201 NDG trial design. J. Clin. Oncol. 42, TPS2096\u2013TPS2096 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2299_CR362","volume":"4","author":"AS Chi","year":"2020","unstructured":"Chi, A. S. et al. Exploring predictors of response to dacomitinib in EGFR-amplified recurrent glioblastoma. JCO Precis. Oncol. 4, PO.19.00295 (2020).","journal-title":"JCO Precis. Oncol."},{"key":"2299_CR363","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13046-019-1289-6","volume":"38","author":"D Han","year":"2019","unstructured":"Han, D. et al. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J. Exp. Clin. Cancer Res. 38, 289 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2299_CR364","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2024.100329","volume":"79","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis. Clinics 79, 100329 (2024).","journal-title":"Clinics"},{"key":"2299_CR365","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-024-06900-x","volume":"17","author":"LR Neitzel","year":"2024","unstructured":"Neitzel, L. R., Fuller, D. T., Williams, C. H. & Hong, C. C. Inhibition of GPR68 kills glioblastoma in zebrafish xenograft models. BMC Res. Notes 17, 235 (2024).","journal-title":"BMC Res. Notes"},{"key":"2299_CR366","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-023-00468-1","volume":"13","author":"CH Williams","year":"2024","unstructured":"Williams, C. H. et al. GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment. Exp. Hematol. Oncol. 13, 13 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"2299_CR367","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/s41588-024-01880-x","volume":"56","author":"HJ Jang","year":"2024","unstructured":"Jang, H. J. et al. Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells. Nat. Genet 56, 1903\u20131913 (2024).","journal-title":"Nat. Genet"},{"key":"2299_CR368","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med. 389, 589\u2013601 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2299_CR369","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.3390\/cancers16162852","volume":"16","author":"AB Jones","year":"2024","unstructured":"Jones, A. B. et al. Temozolomide and the PARP inhibitor Niraparib enhance expression of natural killer group 2D ligand ULBP1 and gamma-delta T cell cytotoxicity in glioblastoma. Cancers 16, 2852 (2024).","journal-title":"Cancers"},{"key":"2299_CR370","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.critrevonc.2018.12.002","volume":"135","author":"M Caccese","year":"2019","unstructured":"Caccese, M., Indraccolo, S., Zagonel, V. & Lombardi, G. PD-1\/PD-L1 immune-checkpoint inhibitors in glioblastoma: a concise review. Crit. Rev. Oncol. Hematol. 135, 128\u2013134 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2299_CR371","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477\u2013486 (2019).","journal-title":"Nat. Med."},{"key":"2299_CR372","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.clon.2016.04.042","volume":"28","author":"T Carter","year":"2016","unstructured":"Carter, T., Shaw, H., Cohn-Brown, D., Chester, K. & Mulholland, P. Ipilimumab and Bevacizumab in Glioblastoma. Clin. Oncol. 28, 622\u2013626 (2016).","journal-title":"Clin. Oncol."},{"key":"2299_CR373","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","volume":"476","author":"S Xu","year":"2020","unstructured":"Xu, S., Tang, L., Li, X., Fan, F. & Liu, Z. Immunotherapy for glioma: current management and future application. Cancer Lett. 476, 1\u201312 (2020).","journal-title":"Cancer Lett."},{"key":"2299_CR374","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2051-1426-2-21","volume":"2","author":"M Li","year":"2014","unstructured":"Li, M. et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J. Immunother. Cancer 2, 21 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"2299_CR375","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fphar.2020.00368","volume":"11","author":"H Gr\u00e9goire","year":"2020","unstructured":"Gr\u00e9goire, H. et al. Targeting tumor associated macrophages to overcome conventional treatment resistance in glioblastoma. Front. Pharmacol. 11, 368 (2020).","journal-title":"Front. Pharmacol."},{"key":"2299_CR376","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.3390\/biomedicines11102621","volume":"11","author":"S Singh","year":"2023","unstructured":"Singh, S. et al. Small molecule targeting immune cells: a novel approach for cancer treatment. Biomedicines 11, 2621 (2023).","journal-title":"Biomedicines"},{"key":"2299_CR377","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.3389\/fimmu.2019.02683","volume":"10","author":"MC Burger","year":"2019","unstructured":"Burger, M. C. et al. CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy. Front. Immunol. 10, 2683 (2019).","journal-title":"Front. Immunol."},{"key":"2299_CR378","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3390\/ijms24032111","volume":"24","author":"T Morimoto","year":"2023","unstructured":"Morimoto, T. et al. Natural killer cell-based immunotherapy against glioblastoma. Int. J. Mol. Sci. 24, 2111 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR379","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"2299_CR380","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41591-024-03138-9","volume":"30","author":"CR Chokshi","year":"2024","unstructured":"Chokshi, C. R. et al. Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells. Nat. Med. 30, 2936\u20132946 (2024).","journal-title":"Nat. Med."},{"key":"2299_CR381","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41392-023-01637-8","volume":"8","author":"B Dewdney","year":"2023","unstructured":"Dewdney, B. et al. From signaling pathways to targeted therapies: unraveling glioblastoma\u2019s secrets and harnessing two decades of progress. Signal Transduct. Target Ther. 8, 400 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2299_CR382","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1038\/s41388-022-02294-x","volume":"41","author":"R Lane","year":"2022","unstructured":"Lane, R. et al. PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1\/p38MAPK signaling. Oncogene 41, 2749\u20132763 (2022).","journal-title":"Oncogene"},{"key":"2299_CR383","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/neuonc\/nox105","volume":"19","author":"JM Sep\u00falveda-S\u00e1nchez","year":"2017","unstructured":"Sep\u00falveda-S\u00e1nchez, J. M. et al. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro Oncol. 19, 1522\u20131531 (2017).","journal-title":"Neuro Oncol."},{"key":"2299_CR384","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/1535-7163.MCT-14-0736","volume":"14","author":"C Zahonero","year":"2015","unstructured":"Zahonero, C. et al. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol. Cancer Ther. 14, 1548\u20131558 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"2299_CR385","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/JCO.18.01207","volume":"37","author":"PY Wen","year":"2019","unstructured":"Wen, P. Y. et al. Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial. J. Clin. Oncol. 37, 741\u2013750 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2299_CR386","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/neuonc\/not139","volume":"16","author":"J Kahn","year":"2014","unstructured":"Kahn, J. et al. The mTORC1\/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro Oncol. 16, 29\u201337 (2014).","journal-title":"Neuro Oncol."},{"key":"2299_CR387","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"X Peng","year":"2023","unstructured":"Peng, X. et al. Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair. Signal Transduct. Target. Ther. 8, 1\u20134 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2299_CR388","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202307747","volume":"11","author":"X Peng","year":"2024","unstructured":"Peng, X. et al. Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma. Adv. Sci. 11, e2307747 (2024).","journal-title":"Adv. Sci."},{"key":"2299_CR389","first-page":"CD011773","volume":"7","author":"S Parasramka","year":"2017","unstructured":"Parasramka, S., Talari, G., Rosenfeld, M., Guo, J. & Villano, J. L. Procarbazine, lomustine and vincristine for recurrent high-grade glioma. Cochrane Database Syst. Rev. 7, CD011773 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2299_CR390","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11060-018-2989-z","volume":"140","author":"JD Palmer","year":"2018","unstructured":"Palmer, J. D. et al. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? J. Neurooncol. 140, 623\u2013628 (2018).","journal-title":"J. Neurooncol."},{"key":"2299_CR391","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11060-017-2383-2","volume":"132","author":"M Azoulay","year":"2017","unstructured":"Azoulay, M. et al. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution. J. Neurooncol. 132, 419\u2013426 (2017).","journal-title":"J. Neurooncol."},{"key":"2299_CR392","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi, A. B., Lim, M., DeWeese, T. L. & Drake, C. G. Radiation and checkpoint blockade immunotherapy: radiosensitization and potential mechanisms of synergy. Lancet Oncol. 16, e498\u2013e509 (2015).","journal-title":"Lancet Oncol."},{"key":"2299_CR393","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","volume":"2","author":"S Demaria","year":"2016","unstructured":"Demaria, S., Coleman, C. N. & Formenti, S. C. Radiotherapy: changing the Game in Immunotherapy. Trends Cancer 2, 286\u2013294 (2016).","journal-title":"Trends Cancer"},{"key":"2299_CR394","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"2299_CR395","doi-asserted-by":"crossref","unstructured":"Xiong, Z. et al. Glioblastoma vaccines: past, present, and opportunities. eBioMedicine 100, (2024).","DOI":"10.1016\/j.ebiom.2023.104963"},{"key":"2299_CR396","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s44178-022-00021-w","volume":"1","author":"T Yang","year":"2022","unstructured":"Yang, T. et al. Peptide vaccine against glioblastoma: from bench to bedside. Holist. Integ. Oncol. 1, 21 (2022).","journal-title":"Holist. Integ. Oncol."},{"key":"2299_CR397","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos, P. M. & Butterfield, L. H. Dendritic cell-based cancer vaccines. J. Immunol. 200, 443\u2013449 (2018).","journal-title":"J. Immunol."},{"key":"2299_CR398","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308280","volume":"11","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. rWTC-MBTA vaccine induces potent adaptive immune responses against glioblastomas via dynamic activation of dendritic cells. Adv. Sci. 11, e2308280 (2024).","journal-title":"Adv. Sci."},{"key":"2299_CR399","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526\u2013543 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2299_CR400","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"2299_CR401","doi-asserted-by":"crossref","unstructured":"Xie, Z., Chen, M., Lian, J., Wang, H. & Ma, J. Glioblastoma-on-a-chip construction and therapeutic applications. Front. Oncol. 13, (2023).","DOI":"10.3389\/fonc.2023.1183059"},{"key":"2299_CR402","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/ng.3806","volume":"49","author":"J-K Lee","year":"2017","unstructured":"Lee, J.-K. et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat. Genet. 49, 594\u2013599 (2017).","journal-title":"Nat. Genet."},{"key":"2299_CR403","doi-asserted-by":"publisher","first-page":"N17","DOI":"10.1227\/01.neu.0000489888.02840.33","volume":"79","author":"S Chakraborty","year":"2016","unstructured":"Chakraborty, S., Schneider, J. & Boockvar, J. A. Transdifferentiation induced neural stem cells for the treatment of malignant gliomas. Neurosurgery 79, N17\u2013N18 (2016).","journal-title":"Neurosurgery"},{"key":"2299_CR404","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10593","volume":"7","author":"JR Bag\u00f3","year":"2016","unstructured":"Bag\u00f3, J. R. et al. Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. Nat. Commun. 7, 10593 (2016).","journal-title":"Nat. Commun."},{"key":"2299_CR405","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/jnr.21983","volume":"87","author":"SN Magge","year":"2009","unstructured":"Magge, S. N. et al. Role of monocyte chemoattractant protein-1 (MCP-1\/CCL2) in migration of neural progenitor cells toward glial tumors. J. Neurosci. Res. 87, 1547\u20131555 (2009).","journal-title":"J. Neurosci. Res."},{"key":"2299_CR406","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3390\/ijms22052258","volume":"22","author":"AY Benmelouka","year":"2021","unstructured":"Benmelouka, A. Y. et al. Neural stem cell-based therapies and glioblastoma management: current evidence and clinical challenges. Int. J. Mol. Sci. 22, 2258 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR407","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/neuonc\/noz138","volume":"21","author":"AB Satterlee","year":"2019","unstructured":"Satterlee, A. B., Dunn, D. E., Lo, D. C., Khagi, S. & Hingtgen, S. Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma. Neuro Oncol. 21, 1552\u20131564 (2019).","journal-title":"Neuro Oncol."},{"key":"2299_CR408","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jneuroim.2009.10.017","volume":"218","author":"S Gunnarsson","year":"2010","unstructured":"Gunnarsson, S. et al. Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFN gamma-transduced tumor cell immunotherapy of experimental glioma. J. Neuroimmunol. 218, 140\u2013144 (2010).","journal-title":"J. Neuroimmunol."},{"key":"2299_CR409","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41417-020-00219-y","volume":"28","author":"J Portnow","year":"2021","unstructured":"Portnow, J. et al. Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients. Cancer Gene Ther. 28, 294\u2013306 (2021).","journal-title":"Cancer Gene Ther."},{"key":"2299_CR410","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","volume":"22","author":"J Fares","year":"2021","unstructured":"Fares, J. et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosedmalignant glioma: a first-in-human, phase 1 clinical trial. Lancet Oncol. 22, 1103\u20131114 (2021).","journal-title":"Lancet Oncol."},{"key":"2299_CR411","doi-asserted-by":"publisher","first-page":"983","DOI":"10.5966\/sctm.2012-0177","volume":"2","author":"MZ Metz","year":"2013","unstructured":"Metz, M. Z. et al. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Transl. Med. 2, 983\u2013992 (2013).","journal-title":"Stem Cells Transl. Med."},{"key":"2299_CR412","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.cell.2019.01.051","volume":"176","author":"S Gujar","year":"2019","unstructured":"Gujar, S., Bell, J. & Diallo, J.-S. SnapShot: cancer immunotherapy with oncolytic viruses. Cell 176, 1240\u20131240.e1 (2019).","journal-title":"Cell"},{"key":"2299_CR413","doi-asserted-by":"publisher","first-page":"672508","DOI":"10.3389\/fonc.2021.672508","volume":"11","author":"SC Frederico","year":"2021","unstructured":"Frederico, S. C. et al. Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma. Front. Oncol. 11, 672508 (2021).","journal-title":"Front. Oncol."},{"key":"2299_CR414","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo, T. et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 1630\u20131639 (2022).","journal-title":"Nat. Med."},{"key":"2299_CR415","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/mt.2014.22","volume":"22","author":"JM Markert","year":"2014","unstructured":"Markert, J. M. et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol. Ther. 22, 1048\u20131055 (2014).","journal-title":"Mol. Ther."},{"key":"2299_CR416","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","volume":"10","author":"EA Chiocca","year":"2004","unstructured":"Chiocca, E. A. et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. 10, 958\u2013966 (2004).","journal-title":"Mol. Ther."},{"key":"2299_CR417","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/mt.2014.21","volume":"22","author":"KP Kicielinski","year":"2014","unstructured":"Kicielinski, K. P. et al. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol. Ther. 22, 1056\u20131062 (2014).","journal-title":"Mol. Ther."},{"key":"2299_CR418","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/gt.2012.62","volume":"20","author":"C Allen","year":"2013","unstructured":"Allen, C. et al. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther. 20, 444\u2013449 (2013).","journal-title":"Gene Ther."},{"key":"2299_CR419","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","volume":"13","author":"AI Freeman","year":"2006","unstructured":"Freeman, A. I. et al. Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13, 221\u2013228 (2006).","journal-title":"Mol. Ther."},{"key":"2299_CR420","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150\u2013161 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2299_CR421","doi-asserted-by":"publisher","unstructured":"Hamad, A. & Chumakov, S. P. Engineering a recombinant Herpesvirus saimiri strain by co-culturing transfected and permissive cells. Bull. RSMU 37\u201344 https:\/\/doi.org\/10.24075\/brsmu.2019.079 (2019).","DOI":"10.24075\/brsmu.2019.079"},{"key":"2299_CR422","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1007\/s12035-018-1240-4","volume":"56","author":"JH Azambuja","year":"2019","unstructured":"Azambuja, J. H. et al. CD73 Downregulation decreases in vitro and in vivo glioblastoma growth. Mol. Neurobiol. 56, 3260\u20133279 (2019).","journal-title":"Mol. Neurobiol."},{"key":"2299_CR423","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","volume":"26","author":"S Goswami","year":"2020","unstructured":"Goswami, S. et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat. Med. 26, 39\u201346 (2020).","journal-title":"Nat. Med."},{"key":"2299_CR424","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"2299_CR425","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1158\/1078-0432.CCR-17-1799","volume":"23","author":"E P\u00e9rez-Ruiz","year":"2017","unstructured":"P\u00e9rez-Ruiz, E., Etxeberria, I., Rodriguez-Ruiz, M. E. & Melero, I. Anti-CD137 and PD-1\/PD-L1 antibodies en route toward clinical synergy. Clin. Cancer Res. 23, 5326\u20135328 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR426","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","volume":"23","author":"NH Segal","year":"2017","unstructured":"Segal, N. H. et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin. Cancer Res. 23, 1929\u20131936 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR427","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119.e10 (2017).","journal-title":"Cell"},{"key":"2299_CR428","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2020.00683","volume":"11","author":"T Shi","year":"2020","unstructured":"Shi, T., Song, X., Wang, Y., Liu, F. & Wei, J. Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment. Front. Immunol. 11, 683 (2020).","journal-title":"Front. Immunol."},{"key":"2299_CR429","first-page":"493","volume":"19","author":"J Hardcastle","year":"2017","unstructured":"Hardcastle, J. et al. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol. 19, 493\u2013502 (2017).","journal-title":"Neuro Oncol."},{"key":"2299_CR430","doi-asserted-by":"publisher","first-page":"eaam7577","DOI":"10.1126\/scitranslmed.aam7577","volume":"10","author":"A Samson","year":"2018","unstructured":"Samson, A. et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci. Transl. Med. 10, eaam7577 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2299_CR431","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2217\/imt-2018-0009","volume":"10","author":"D Saha","year":"2018","unstructured":"Saha, D., Martuza, R. L. & Rabkin, S. D. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. Immunotherapy 10, 779\u2013786 (2018).","journal-title":"Immunotherapy"},{"key":"2299_CR432","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/1078-0432.CCR-17-2871","volume":"24","author":"D Migliorini","year":"2018","unstructured":"Migliorini, D. et al. CAR T-cell therapies in glioblastoma: a first look. Clin. Cancer Res. 24, 535\u2013540 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2299_CR433","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","volume":"9","author":"S Guedan","year":"2018","unstructured":"Guedan, S. & Alemany, R. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge. Front. Immunol. 9, 2460 (2018).","journal-title":"Front. Immunol."},{"key":"2299_CR434","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/neuonc\/nox037","volume":"19","author":"LA Mitchell","year":"2017","unstructured":"Mitchell, L. A. et al. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Neuro Oncol. 19, 930\u2013939 (2017).","journal-title":"Neuro Oncol."},{"key":"2299_CR435","doi-asserted-by":"publisher","first-page":"662064","DOI":"10.3389\/fnins.2021.662064","volume":"15","author":"L Maggs","year":"2021","unstructured":"Maggs, L., Cattaneo, G., Dal, A. E., Moghaddam, A. S. & Ferrone, S. C. A. R. T. Cell-based immunotherapy for the treatment of glioblastoma. Front. Neurosci. 15, 662064 (2021).","journal-title":"Front. Neurosci."},{"key":"2299_CR436","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.semcancer.2022.06.001","volume":"86","author":"SE Wang","year":"2022","unstructured":"Wang, S. E. Extracellular vesicles in cancer therapy. Semin. Cancer Biol. 86, 296\u2013309 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2299_CR437","doi-asserted-by":"publisher","first-page":"118122","DOI":"10.1016\/j.lfs.2020.118122","volume":"257","author":"S Gu","year":"2020","unstructured":"Gu, S. et al. Berberine inhibits cancer cells growth by suppressing fatty acid synthesis and biogenesis of extracellular vesicles. Life Sci. 257, 118122 (2020).","journal-title":"Life Sci."},{"key":"2299_CR438","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11060-013-1235-y","volume":"115","author":"NA Atai","year":"2013","unstructured":"Atai, N. A. et al. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. J. Neurooncol. 115, 343\u2013351 (2013).","journal-title":"J. Neurooncol."},{"key":"2299_CR439","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/ijms21030727","volume":"21","author":"HS Joo","year":"2020","unstructured":"Joo, H. S., Suh, J. H., Lee, H. J., Bang, E. S. & Lee, J. M. Current knowledge and future perspectives on mesenchymal stem cell-derived exosomes as a new therapeutic agent. Int. J. Mol. Sci. 21, 727 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2299_CR440","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.gene.2014.10.038","volume":"554","author":"H Guo","year":"2015","unstructured":"Guo, H., Wu, L., Yang, Q., Ye, M. & Zhu, X. Functional linc-POU3F3 is overexpressed and contributes to tumorigenesis in glioma. Gene 554, 114\u2013119 (2015).","journal-title":"Gene"},{"key":"2299_CR441","doi-asserted-by":"publisher","first-page":"130065","DOI":"10.1016\/j.bbagen.2021.130065","volume":"1866","author":"S Mukherjee","year":"2022","unstructured":"Mukherjee, S. & Pillai, P. P. Current insights on extracellular vesicle-mediated glioblastoma progression: Implications in drug resistance and epithelial\u2013mesenchymal transition. Biochim. Biophys. Acta Gen. Subj. 1866, 130065 (2022).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"2299_CR442","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.3390\/cancers15184425","volume":"15","author":"GL Liguori","year":"2023","unstructured":"Liguori, G. L. & Kralj-Igli\u010d, V. Pathological and therapeutic significance of tumor-derived extracellular vesicles in cancer cell migration and metastasis. Cancers 15, 4425 (2023).","journal-title":"Cancers"},{"key":"2299_CR443","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2023.04.038","volume":"358","author":"A Macedo-Pereira","year":"2023","unstructured":"Macedo-Pereira, A., Martins, C., Lima, J. & Sarmento, B. Digging the intercellular crosstalk via extracellular vesicles: may exosomes be the drug delivery solution for target glioblastoma? J. Control Release 358, 98\u2013115 (2023).","journal-title":"J. Control Release"},{"key":"2299_CR444","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/life13040964","volume":"13","author":"A Galardi","year":"2023","unstructured":"Galardi, A. et al. Recent advancements on the use of exosomes as drug carriers for the treatment of glioblastoma. Life 13, 964 (2023).","journal-title":"Life"},{"key":"2299_CR445","doi-asserted-by":"publisher","first-page":"956563","DOI":"10.3389\/fbioe.2022.956563","volume":"10","author":"A Dalmizrak","year":"2022","unstructured":"Dalmizrak, A. & Dalmizrak, O. Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer. Front. Bioeng. Biotechnol. 10, 956563 (2022).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"2299_CR446","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2013.02.019","volume":"335","author":"M Katakowski","year":"2013","unstructured":"Katakowski, M. et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 335, 201\u2013204 (2013).","journal-title":"Cancer Lett."},{"key":"2299_CR447","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/neuonc\/nox152","volume":"20","author":"FM Lang","year":"2018","unstructured":"Lang, F. M. et al. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. Neuro Oncol. 20, 380\u2013390 (2018).","journal-title":"Neuro Oncol."},{"key":"2299_CR448","doi-asserted-by":"publisher","first-page":"e2713","DOI":"10.1038\/cddis.2017.117","volume":"8","author":"M Fareh","year":"2017","unstructured":"Fareh, M. et al. Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth. Cell Death Dis. 8, e2713\u2013e2713 (2017).","journal-title":"Cell Death Dis."},{"key":"2299_CR449","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3389\/fonc.2019.00782","volume":"9","author":"H Monfared","year":"2019","unstructured":"Monfared, H., Jahangard, Y., Nikkhah, M., Mirnajafi-Zadeh, J. & Mowla, S. J. Potential therapeutic effects of exosomes packed with a mir-21-sponge construct in a rat model of glioblastoma. Front. Oncol. 9, 782 (2019).","journal-title":"Front. Oncol."},{"key":"2299_CR450","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.60","volume":"2","author":"JL Munoz","year":"2013","unstructured":"Munoz, J. L. et al. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol. Ther. Nucleic Acids 2, e126 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2299_CR451","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/pharmaceutics14051002","volume":"14","author":"H Lee","year":"2022","unstructured":"Lee, H. et al. Glioblastoma-derived exosomes as nanopharmaceutics for improved glioma treatment. Pharmaceutics 14, 1002 (2022).","journal-title":"Pharmaceutics"},{"key":"2299_CR452","doi-asserted-by":"publisher","first-page":"12341","DOI":"10.1021\/acsami.7b18135","volume":"10","author":"Z Ye","year":"2018","unstructured":"Ye, Z. et al. Methotrexate-loaded extracellular vesicles functionalized with therapeutic and targeted peptides for the treatment of glioblastoma multiforme. ACS Appl. Mater. Interfaces 10, 12341\u201312350 (2018).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2299_CR453","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/cancers14030735","volume":"14","author":"M Tibensky","year":"2022","unstructured":"Tibensky, M. et al. Gene-directed enzyme\/prodrug therapy of rat brain tumor mediated by human mesenchymal stem cell suicide gene extracellular vesicles in vitro and in vivo. Cancers 14, 735 (2022).","journal-title":"Cancers"},{"key":"2299_CR454","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120784","volume":"273","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy. Biomater 273, 120784 (2021).","journal-title":"Biomater"},{"key":"2299_CR455","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.biomaterials.2018.06.029","volume":"178","author":"G Jia","year":"2018","unstructured":"Jia, G. et al. NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. Biomater 178, 302\u2013316 (2018).","journal-title":"Biomater"},{"key":"2299_CR456","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.18632\/aging.202424","volume":"13","author":"Z Z","year":"2021","unstructured":"Z, Z. et al. MicroRNA-29a-3p delivery via exosomes derived from engineered human mesenchymal stem cells exerts tumour suppressive effects by inhibiting migration and vasculogenic mimicry in glioma. Aging 13, 5055\u20135068 (2021).","journal-title":"Aging"},{"key":"2299_CR457","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s12031-015-0506-9","volume":"56","author":"N Bu","year":"2015","unstructured":"Bu, N. et al. Exosomes from dendritic cells loaded with chaperone-rich cell lysates elicit a potent T cell immune response against intracranial glioma in mice. J. Mol. Neurosci. 56, 631\u2013643 (2015).","journal-title":"J. Mol. Neurosci."},{"key":"2299_CR458","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/biology11101483","volume":"11","author":"D Ge\u010dys","year":"2022","unstructured":"Ge\u010dys, D. et al. Internalization of RGD-engineered extracellular vesicles by glioblastoma cells. Biology 11, 1483 (2022).","journal-title":"Biology"},{"key":"2299_CR459","first-page":"vdaa132","volume":"2","author":"BC Parker Kerrigan","year":"2020","unstructured":"Parker Kerrigan, B. C. et al. RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. Neurooncol. Adv. 2, vdaa132 (2020).","journal-title":"Neurooncol. Adv."},{"key":"2299_CR460","doi-asserted-by":"publisher","first-page":"16432","DOI":"10.1021\/acsnano.2c12857","volume":"17","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Engineered extracellular vesicle-delivered CRISPR\/Cas9 for radiotherapy sensitization of glioblastoma. ACS Nano 17, 16432\u201316447 (2023).","journal-title":"ACS Nano"},{"key":"2299_CR461","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s12031-020-01639-z","volume":"70","author":"A Bagherian","year":"2020","unstructured":"Bagherian, A. et al. Combination therapy with nanomicellar-curcumin and temozolomide for in vitro therapy of glioblastoma multiforme via Wnt signaling pathways. J. Mol. Neurosci. 70, 1471\u20131483 (2020).","journal-title":"J. Mol. Neurosci."},{"key":"2299_CR462","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s13346-021-01017-1","volume":"12","author":"AB Behrooz","year":"2022","unstructured":"Behrooz, A. B. et al. Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance. Drug Deliv. Transl. Res. 12, 1253\u20131269 (2022).","journal-title":"Drug Deliv. Transl. Res."},{"key":"2299_CR463","doi-asserted-by":"publisher","first-page":"120714","DOI":"10.1016\/j.ijpharm.2021.120714","volume":"603","author":"NN Ferreira","year":"2021","unstructured":"Ferreira, N. N. et al. Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system. Int. J. Pharm. 603, 120714 (2021).","journal-title":"Int. J. Pharm."},{"key":"2299_CR464","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.colsurfb.2018.09.047","volume":"173","author":"S Lakkadwala","year":"2019","unstructured":"Lakkadwala, S. & Singh, J. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model. Colloids Surf. B Biointerfaces 173, 27\u201335 (2019).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"2299_CR465","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jconrel.2019.06.033","volume":"307","author":"S Lakkadwala","year":"2019","unstructured":"Lakkadwala, S., dos Santos Rodrigues, B., Sun, C. & Singh, J. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. J. Control Release 307, 247\u2013260 (2019).","journal-title":"J. Control Release"},{"key":"2299_CR466","doi-asserted-by":"publisher","first-page":"117943","DOI":"10.1016\/j.lfs.2020.117943","volume":"256","author":"F Madani","year":"2020","unstructured":"Madani, F. et al. Paclitaxel\/methotrexate coloaded PLGA nanoparticles in glioblastoma treatment: Formulation development and in vitro antitumor activity evaluation. Life Sci. 256, 117943 (2020).","journal-title":"Life Sci."},{"key":"2299_CR467","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1021\/acsnano.5b07375","volume":"10","author":"M Tamborini","year":"2016","unstructured":"Tamborini, M. et al. A combined approach employing chlorotoxin-nanovectors and low dose radiation to reach infiltrating tumor niches in glioblastoma. ACS Nano 10, 2509\u20132520 (2016).","journal-title":"ACS Nano"},{"key":"2299_CR468","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.7150\/thno.40298","volume":"10","author":"J Yang","year":"2020","unstructured":"Yang, J., Shi, Z., Liu, R., Wu, Y. & Zhang, X. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology. Theranostics 10, 3223\u20133239 (2020).","journal-title":"Theranostics"},{"key":"2299_CR469","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12951-020-00751-x","volume":"19","author":"C He","year":"2021","unstructured":"He, C. et al. LRP1-mediated pH-sensitive polymersomes facilitate combination therapy of glioblastoma in vitro and in vivo. J. Nanobiotechnol. 19, 29 (2021).","journal-title":"J. Nanobiotechnol."},{"key":"2299_CR470","doi-asserted-by":"publisher","first-page":"114822","DOI":"10.1016\/j.addr.2023.114822","volume":"197","author":"R Qiao","year":"2023","unstructured":"Qiao, R. et al. Magnetic iron oxide nanoparticles for brain imaging and drug delivery. Adv. Drug Deliv. Rev. 197, 114822 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2299_CR471","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1021\/acsbiomaterials.1c01023","volume":"7","author":"S Chibh","year":"2021","unstructured":"Chibh, S., Katoch, V., Singh, M., Prakash, B. & Panda, J. J. Miniatured fluidics-mediated modular self-assembly of anticancer drug-amino acid composite microbowls for combined chemo-photodynamic therapy in glioma. ACS Biomater. Sci. Eng. 7, 5654\u20135665 (2021).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"2299_CR472","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/nano11040912","volume":"11","author":"M Maturi","year":"2021","unstructured":"Maturi, M. et al. Synthesis of ultrasmall single-crystal gold\u2013silver alloy nanotriangles and their application in photothermal therapy. Nanomater 11, 912 (2021).","journal-title":"Nanomater"},{"key":"2299_CR473","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1021\/acs.molpharmaceut.2c00083","volume":"19","author":"Y Yu","year":"2022","unstructured":"Yu, Y. et al. Efficacy of temozolomide-conjugated gold nanoparticle photothermal therapy of drug-resistant glioblastoma and its mechanism study. Mol. Pharm. 19, 1219\u20131229 (2022).","journal-title":"Mol. Pharm."},{"key":"2299_CR474","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1021\/acsabm.0c00386","volume":"3","author":"C Zhang","year":"2020","unstructured":"Zhang, C. et al. Hypocrellin-based multifunctional phototheranostic agent for nir-triggered targeted chemo\/photodynamic\/photothermal synergistic therapy against glioblastoma. ACS Appl. Bio Mater. 3, 3817\u20133826 (2020).","journal-title":"ACS Appl. Bio Mater."},{"key":"2299_CR475","doi-asserted-by":"publisher","first-page":"682151","DOI":"10.3389\/fneur.2021.682151","volume":"12","author":"AJ Schupper","year":"2021","unstructured":"Schupper, A. J. et al. Fluorescence-guided surgery: a review on timing and use in brain tumor surgery. Front. Neurol. 12, 682151 (2021).","journal-title":"Front. Neurol."},{"key":"2299_CR476","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202106082","volume":"34","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Brain-targeted aggregation-induced-emission nanoparticles with near-infrared imaging at 1550 nm boosts orthotopic glioblastoma theranostics. Adv. Mater. 34, e2106082 (2022).","journal-title":"Adv. Mater."},{"key":"2299_CR477","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202008802","volume":"33","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Upregulating aggregation-induced-emission nanoparticles with blood-tumor-barrier permeability for precise photothermal eradication of brain tumors and induction of local immune responses. Adv. Mater. 33, e2008802 (2021).","journal-title":"Adv. Mater."},{"key":"2299_CR478","doi-asserted-by":"publisher","first-page":"52092","DOI":"10.1021\/acsami.1c09518","volume":"13","author":"WC Chien","year":"2021","unstructured":"Chien, W. C. et al. MCP-1-Functionalized, core-shell gold nanorod@iron-based metal-organic framework (MCP-1\/GNR@MIL-100(Fe)) for photothermal therapy. ACS Appl. Mater. Interfaces 13, 52092\u201352105 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2299_CR479","doi-asserted-by":"publisher","first-page":"1800025","DOI":"10.1002\/adfm.201800025","volume":"28","author":"J Kuang","year":"2018","unstructured":"Kuang, J. et al. iRGD Modified Chemo-immunotherapeutic Nanoparticles For Enhanced Immunotherapy Against Glioblastoma. Adv. Funct. Mater. 28, 1800025 (2018).","journal-title":"Adv. Funct. Mater."},{"key":"2299_CR480","first-page":"1365","volume":"13","author":"P Kadiyala","year":"2019","unstructured":"Kadiyala, P. et al. High Density Lipoprotein-mimicking Nanodiscs For Chemo-immunotherapy Against Glioblastoma Multiforme. ACS Nano 13, 1365\u20131384 (2019).","journal-title":"ACS Nano"},{"key":"2299_CR481","first-page":"1","volume":"13","author":"Z Chen","year":"2022","unstructured":"Chen, Z. et al. Disruption of \u03b2-catenin-mediated negative feedback reinforces cAMP-induced neuronal differentiation in glioma stem cells. Cell Death Dis. 13, 1\u201313 (2022).","journal-title":"Cell Death Dis."},{"key":"2299_CR482","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"R-X Huang","year":"2020","unstructured":"Huang, R.-X. & Zhou, P.-K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct. Target Ther. 5, 60 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2299_CR483","doi-asserted-by":"publisher","first-page":"100987","DOI":"10.1016\/j.gendis.2023.04.022","volume":"11","author":"Y He","year":"2024","unstructured":"He, Y. et al. The roles and mechanisms of SREBP1 in cancer development and drug response. Genes Dis. 11, 100987 (2024).","journal-title":"Genes Dis."},{"key":"2299_CR484","doi-asserted-by":"publisher","first-page":"100469","DOI":"10.1016\/j.xcrm.2021.100469","volume":"2","author":"IC Hvinden","year":"2021","unstructured":"Hvinden, I. C., Cadoux-Hudson, T., Schofield, C. J. & McCullagh, J. S. O. Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations. Cell Rep. Med. 2, 100469 (2021).","journal-title":"Cell Rep. Med."},{"key":"2299_CR485","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim, M., Xia, Y., Bettegowda, C. & Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422\u2013442 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2299_CR486","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. 25, 123\u2013134 (2023).","journal-title":"Neuro Oncol."},{"key":"2299_CR487","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24, 1935\u20131949 (2022).","journal-title":"Neuro Oncol."},{"key":"2299_CR488","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","volume":"41","author":"MM Staron","year":"2014","unstructured":"Staron, M. M. et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 41, 802\u2013814 (2014).","journal-title":"Immunity"},{"key":"2299_CR489","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"2299_CR490","doi-asserted-by":"publisher","first-page":"923","DOI":"10.20892\/j.issn.2095-3941.2020.0338","volume":"17","author":"Z Zeng","year":"2020","unstructured":"Zeng, Z., Wei, F. & Ren, X. Exhausted T cells and epigenetic status. Cancer Biol. Med. 17, 923\u2013936 (2020).","journal-title":"Cancer Biol. Med."},{"key":"2299_CR491","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang, C.-H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"2299_CR492","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/j.celrep.2019.04.022","volume":"27","author":"J Qiu","year":"2019","unstructured":"Qiu, J. et al. Acetate Promotes T cell effector function during glucose restriction. Cell Rep. 27, 2063\u20132074.e5 (2019).","journal-title":"Cell Rep."},{"key":"2299_CR493","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco, F., Jaccard, A., Romero, P., Yu, Y.-R. & Ho, P.-C. Metabolic and epigenetic regulation of T-cell exhaustion. Nat. Metab. 2, 1001\u20131012 (2020).","journal-title":"Nat. Metab."},{"key":"2299_CR494","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41590-024-01918-6","volume":"25","author":"D Soll","year":"2024","unstructured":"Soll, D. et al. Sodium chloride in the tumor microenvironment enhances T cell metabolic fitness and cytotoxicity. Nat. Immunol. 25, 1830\u20131844 (2024).","journal-title":"Nat. Immunol."},{"key":"2299_CR495","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41590-024-01923-9","volume":"25","author":"C Scirgolea","year":"2024","unstructured":"Scirgolea, C. et al. NaCl enhances CD8+ T\u2009cell effector functions in cancer immunotherapy. Nat. Immunol. 25, 1845\u20131857 (2024).","journal-title":"Nat. Immunol."},{"key":"2299_CR496","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.14101","volume":"112","author":"A Mishra","year":"2024","unstructured":"Mishra, A., Maiti, R., Mohan, P. & Gupta, P. Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions. Eur. J. Hematol. 112, 211\u2013222 (2024).","journal-title":"Eur. J. Hematol."},{"key":"2299_CR497","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.abc1855","volume":"371","author":"RA Hernandez-Lopez","year":"2021","unstructured":"Hernandez-Lopez, R. A. et al. T cell circuits that sense antigen density with an ultrasensitive threshold. Science 371, 1166\u20131171 (2021).","journal-title":"Science"},{"key":"2299_CR498","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu, G. et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur. J. Immunol. 50, 712\u2013724 (2020).","journal-title":"Eur. J. Immunol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02299-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:42:20Z","timestamp":1752136940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02299-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":498,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2299"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02299-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. The funders had no role in the design or writing of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}